0000087802-15-000009.txt : 20151112
0000087802-15-000009.hdr.sgml : 20151112
20151112141239
ACCESSION NUMBER: 0000087802-15-000009
CONFORMED SUBMISSION TYPE: 10-Q
PUBLIC DOCUMENT COUNT: 9
CONFORMED PERIOD OF REPORT: 20150930
FILED AS OF DATE: 20151112
DATE AS OF CHANGE: 20151112
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: SCIENTIFIC INDUSTRIES INC
CENTRAL INDEX KEY: 0000087802
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 042217279
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: 10-Q
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-06658
FILM NUMBER: 151223486
BUSINESS ADDRESS:
STREET 1: 70 ORVILLE DR
STREET 2: AIRPORT INTERNATIONAL PLZ
CITY: BOHEMIA
STATE: NY
ZIP: 11716
BUSINESS PHONE: 6315674700
MAIL ADDRESS:
STREET 1: 70 ORVILLE DR
CITY: BOHEMIA
STATE: NY
ZIP: 11716
10-Q
1
qsep15.txt
10-Q FOR SEPTEMBER 30, 2015
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
X QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For quarterly period ended September 30, 2015
TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from_________to_________
Commission File Number: 0-6658
___________________________
SCIENTIFIC INDUSTRIES, INC.
_____________________________________________________________________
(Exact name of registrant as specified in its charter)
Delaware 04-2217279
____________________________ _________________________________
(State or other jurisdiction (IRS Employer Identification No.)
of incorporation or
organization)
80 Orville Drive, Suite 102, Bohemia, New York 11716
______________________________________________ _________________
(Address of principal executive offices) (Zip Code)
(631)567-4700
_____________________________________________________________________
(Registrant?s telephone number, including area code)
Not Applicable
_____________________________________________________________________
(Former name, former address and former fiscal year, if changed since
last report)
Indicate by check whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act during the
preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No .
Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a small reporting company.
See the definitions of "large accelerated filer," "accelerated filer" and
"small reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer Accelerated Filer
Non-accelerated filer Smaller reporting company X
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company (as defined
in Rule 12b-2 of the Exchange Act).
Yes X No
The number of shares outstanding of the issuer's common stock par value,
$0.05 per share, as of October 30, 2015 was 1,489,112 shares.
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
ITEM 1 CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED):
Page
____
Condensed Consolidated Balance Sheets 1
Condensed Consolidated Statements of Operations 2
Condensed Consolidated Statements of Comprehensive
Income Loss 3
Condensed Consolidated Statements of Cash Flows 4
Notes to Condensed Consolidated Financial Statements 6
ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF
OPERATIONS 13
ITEM 4 CONTROLS AND PROCEDURES 15
PART II - OTHER INFORMATION
ITEM 6 EXHIBITS AND REPORTS ON FORM 8-K 16
SIGNATURE 17
EXHIBITS 18
PART I-FINANCIAL INFORMATION
Item 1. Financial Statements
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
September 30, June 30,
2015 2015
_____________ __________
Current Assets: (Unaudited)
Cash and cash equivalents $ 530,200 $ 482,000
Restricted cash 300,000 300,000
Investment securities 277,000 281,800
Trade accounts receivable, net 737,400 1,081,700
Inventories 2,343,800 2,213,700
Prepaid expenses and other current assets 145,300 68,600
Deferred taxes 118,000 114,200
_________ _________
Total current assets 4,451,700 4,542,000
Property and equipment at cost, net 222,800 235,200
Intangible assets, net 1,363,000 1,451,900
Goodwill 705,300 705,300
Other assets 52,500 52,500
Deferred taxes 169,400 154,500
__________ __________
Total assets $6,964,700 $7,141,400
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable $ 201,100 $ 227,600
Customer advances 93,500 76,400
Bank line of credit 200,000 -
Notes payable, current portion 200,000 200,000
Accrued expenses and taxes 316,800 519,900
Contingent consideration, current portion 128,900 106,800
__________ __________
Total current liabilities 1,140,300 1,130,700
Contingent consideration payable, less
current portion 137,300 260,300
__________ __________
Total liabilities 1,277,600 1,391,000
__________ __________
Shareholders' equity:
Common stock, $.05 par value; authorized 7,000,000 shares;
1,508,914 outstanding at
September 30, 2015 and June 30, 2015 75,400 75,400
Additional paid-in capital 2,487,300 2,486,700
Accumulated other comprehensive loss ( 7,100) ( 3,300)
Retained earnings 3,183,900 3,244,000
___________ __________
5,739,500 5,802,800
Less common stock held in treasury, at cost,
19,802 shares 52,400 52,400
__________ __________
Total shareholders' equity 5,687,100 5,750,400
__________ __________
Total liabilities and
shareholders' equity $6,964,700 $7,141,400
========== ==========
See notes to unaudited condensed consolidated financial statements
1
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)
For the Three Month
Periods Ended
September 30,
2015 2014
__________ __________
Revenues $1,444,500 $1,662,100
Cost of revenues 849,400 1,161,900
__________ __________
Gross profit 595,100 500,200
__________ __________
Operating expenses:
General and administrative 408,200 326,500
Selling 167,000 295,300
Research and development 85,400 107,100
__________ __________
Total operating expenses 660,600 728,900
__________ __________
Loss from operations ( 65,500) ( 228,700)
__________ __________
Other income (expense):
Investment income 400 800
Other income (expense) ( 4,700) 6,200
Interest expense ( 8,100) ( 1,200)
__________ __________
Total other income (expense), net ( 12,400) 5,800
__________ __________
Loss before income tax benefit ( 77,900) ( 222,900)
__________ __________
Income tax benefit:
Current - ( 57,200)
Deferred ( 17,800) ( 4,400)
__________ __________
Total income tax benefit ( 17,800) ( 61,600)
__________ __________
Net loss ($ 60,100) ($161,300)
========== ==========
Basic loss per common share ($ .04) ($ .11)
======== ========
Diluted loss per common share ($ .04) ($ .11)
======== ========
See notes to unaudited condensed consolidated financial statements
2
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
For the Three Month
Periods Ended
September 30,
2015 2014
__________ __________
Net loss ($ 60,100) ($161,300)
Other comprehensive loss:
Unrealized holding loss
arising during period,
net of tax ( 3,800) ( 700)
__________ __________
Comprehensive loss ($ 63,900) ($162,000)
========== ==========
See notes to unaudited condensed consolidated financial statements
3
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
For the Three Month Periods Ended
Sept. 30, 2015 Sept. 30, 2014
______________ ______________
Operating activities:
Net loss ($ 60,100) ($ 161,300)
___________ ___________
Adjustments to reconcile net loss
to net cash used in operating activities:
Loss on sale of investments - 1,300
Loss on asset disposal 2,700 -
Depreciation and amortization 105,200 110,100
Deferred income taxes ( 17,800) ( 4,400)
Stock-based compensation 600 1,000
Income tax benefit of stock options
exercised - 4,900
Changes in operating assets and liabilities:
Accounts receivable 344,300 ( 38,500)
Inventories ( 130,100) 26,300
Prepaid expenses and other
current assets ( 76,700) ( 61,600)
Other assets - ( 25,400)
Accounts payable ( 26,500) ( 31,500)
Customer advances 17,100 3,300
Accrued expenses and taxes ( 203,100) ( 83,900)
___________ ____________
Total adjustments 15,700 ( 98,400)
___________ ____________
Net cash used in
operating activities ( 44,400) ( 259,700)
___________ ____________
Investing activities:
Redemption of investment securities,
available-for-sale - 75,000
Capital expenditures ( 6,500) ( 19,700)
Purchases of intangible assets - ( 1,100)
___________ ____________
Net cash provided by (used in)
investing activities ( 6,500) 54,200
___________ ____________
Financing activities:
Line of credit proceeds 200,000 200,000
Payment of contingent consideration ( 100,900) ( 98,900)
Proceeds from exercise of stock options - 18,800
Principal payments on note payable ( - ) ( 20,000)
___________ ____________
Net cash provided by
financing activities 99,100 99,900
___________ ____________
See notes to unaudited condensed consolidated financial statements
4
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
For the Three Month Periods Ended
Sept. 30, 2015 Sept. 30, 2014
______________ ______________
Net increase (decrease) in cash and
cash equivalents 48,200 ( 105,600)
Cash and cash equivalents,
beginning of year` 482,000 493,700
_________ __________
Cash and cash equivalents, end of period $ 530,200 $ 388,100
========= ==========
Supplemental disclosures:
Cash paid during the period for:
Income Taxes $ 18,500 $ 3,500
Interest 4,400 1,200
See Note 3 for non-cash investing and financing activities
See notes to unaudited condensed consolidated financial statements
5
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
General: The accompanying unaudited interim
condensed consolidated financial statements are prepared
pursuant to the Securities and Exchange Commission's rules
and regulations for reporting on Form 10-Q. Accordingly,
certain information and footnotes required by accounting
principles generally accepted in the United States for
complete financial statements are not included herein.
The Company believes all adjustments necessary for a
fair presentation of these interim statements have been
included and that they are of a normal and recurring
nature. These interim statements should be read in
conjunction with the Company's financial statements and
notes thereto, included in its Annual Report on Form 10-K,
for the fiscal year ended June 30, 2015. The results for
the three months ended September 30, 2015, are not
necessarily an indication of the results for the full
fiscal year ending June 30, 2016.
1. Summary of significant accounting policies:
Principles of consolidation:
The accompanying consolidated financial statements include the
accounts of Scientific Industries, Inc. ("Scientific", a Delaware
corporation), Altamira Instruments, Inc.("Altamira", a wholly owned
subsidiary and Delaware corporation), Scientific Packaging
Industries, Inc. (an inactive wholly owned subsidiary and New York
corporation) and Scientific Bioprocessing, Inc., ("SBI", a wholly
owned subsidiary and Delaware corporation). All are collectively
referred to as the "Company". All material intercompany balances and
transactions have been eliminated.
2. New Accounting Pronouncements:
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with
Customers amending revenue recognition requirements for multiple-
deliverable revenue arrangements. This update provides guidance on how
revenue is recognized to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the
entity expects to be entitled in exchange for the goods or services. This
determination is made in five steps: (i) identify the contract with the
customer: (ii) identify the performance obligations in the contract; (iii)
determine the transaction price; (iv) allocate the transaction price to the
performance obligations in the contract; and (v) recognize revenue when (or
as) the entity satisfies a performance obligation. In July 2015, the FASB
deferred the effective date to fiscal years beginning after December 15,
2018, or the Company's fiscal year ending June 30, 2020, and early adoption
of the standard is permitted, but not before the original effective date of
December 15, 2017. The Company is evaluating the effect this guidance will
have on the consolidated financial statements and related disclosures.
In June 2014, the FASB issued ASU 2014-12, Compensation - Stock
Compensation (Topic 718): Accounting for Share-Based Payments When the
Terms of an Award Provide that a Performance Target Could be Achieved After
the Requisite Service Period. This update affects reporting entities that
grant their employee's targets that affects vesting could be achieved after
6
the requisite service period. The new standard requires that a performance
target that affects vesting and that could be achieved after the requisite
services period be treated as a performance condition. The new standard
will be effective for the Company beginning July 1, 2016, and early
adoption is permitted. The Company expects the adoption will not have a
material impact on its financial condition, results of operations or cash
flows.
In July 2015, the FASB issued ASU No. 2015-11, "Inventory: Simplifying the
Measurement of Inventory", that requires inventory not measured using
either the last in, first out (LIFO) or the retail inventory method to be
measured at the lower of cost and net realizable value. Net realizable
value is the estimated selling prices in the ordinary course of business,
less reasonably predictable cost of completion, disposal and
transportation. The new standard will be effective for fiscal years
beginning after December 15, 2016, including interim periods within those
fiscal years, and will be applied prospectively. Early adoption is
permitted. The Company is evaluating the impact that this standard will
have on its consolidated financial statements.
3. Acquisition:
On February 26, 2014, the Company acquired substantially all the assets of a
privately owned company consisting principally of inventory, fixed assets,
and intangible assets related to the production and sale of a variety of
laboratory and pharmacy balances and scales. The acquisition was pursuant to
an asset purchase agreement whereby the Company paid the sellers $700,000 in
cash, 126,449 shares of Common Stock valued at $427,500 and agreed to make
additional cash payments based on a percentage of net sales of the business
acquired equal to 8% for the period ending June 30, 2014 annualized, 9% for
the year ending June 30, 2015, 10% for the year ending June 30, 2016 and 11%
for the year ending June 30, 2017, estimated at a present value of $460,000
on the date of acquisition. Payments related to this contingent consideration
for each period are due in September following the fiscal year. Contingent
consideration payments made amounted to $100,900 and $98,900 during the three
months ended September 30, 2015 and 2014, respectively.
The products, which are similar to the Company's other Benchtop Laboratory
Equipment, and in many cases used by the same customers, are marketed under
the Torbal(R) brand. The principal customers are pharmacies, pharmacy schools,
universities, government laboratories, and industries utilizing a precision
scale. The products are sold primarily on a direct basis, including through
the Company's e-commerce site.
Management of the Company allocated the purchase price based on its
valuation of the assets acquired, as follows:
Current assets $ 144,000
Property and equipment 118,100
Goodwill* 115,400
Other intangible assets 1,210,000
__________
Total Purchase Price $1,587,500
==========
*See Note 8, "Goodwill and Other Intangible Assets".
7
Of the $1,210,000 of the acquired other intangible assets, $570,000 was
assigned to technology and websites with a useful life of 5 years, $120,000
was assigned to customer relationships with an estimated useful life of 9
years, $140,000 was assigned to the trade name with an estimated useful
life of 6 years, $110,000 was assigned to the IPR&D with an estimated
useful life of 3 years, and $270,000 was assigned to non-compete agreements
with an estimated useful life of 5 years.
In connection with the acquisition, the Company entered into a three-year
employment agreement with the previous Chief Operating Officer of the
acquired business as President of the Company's new Torbal Division and
Director of Marketing for the Company. The agreement may be extended by
mutual consent for an additional two years.
4. Segment Information and Concentrations:
The Company views its operations as three segments: the manufacture and
marketing of standard benchtop laboratory equipment including the balances
and scales by its Torbal Scales Division for research in university,
hospital and industrial laboratories sold primarily through laboratory
equipment distributors and on a direct basis ("Benchtop Laboratory
Equipment"), the manufacture and marketing of custom-made catalyst research
instruments for universities, government laboratories, and chemical and
petrochemical companies sold on a direct basis ("Catalyst Research
Instruments") and the marketing and production of bioprocessing systems for
laboratory research in the biotechnology industry sold directly to
customers and through distributors ("Bioprocessing Systems").
Segment information is reported as follows:
Benchtop Catalyst Bio- Corporate
Laboratory Research processing and Conso-
Equipment Instruments Systems Other lidated
__________ ___________ __________ _________ ___________
Three months ended September 30, 2015:
Revenues $1,263,000 $ 153,000 $ 28,500 $ - $1,444,500
Foreign Sales 599,000 7,800 - - 606,800
Income (Loss) from
Operations 54,700 ( 82,000) ( 30,100) ( 8,100) ( 65,500)
Assets 4,056,400 1,613,200 730,700 564,400 6,964,700
Long-Lived Asset
Expenditures 6,500 - - - 6,500
Depreciation and
Amortization 73,800 6,900 24,500 - 105,200
8
Benchtop Catalyst Bio- Corporate
Laboratory Research processing and Conso-
Equipment Instruments Systems Other lidated
__________ ___________ __________ _________ ___________
Three months ended September 30, 2014:
Revenues $1,086,400 $ 551,100 $ 24,600 $ - $1,662,100
Foreign Sales 411,100 443,500 - - 854,600
Loss from
Operations ( 118,100) ( 70,200) ( 40,400) - ( 228,700)
Assets 4,074,800 1,507,400 786,600 574,900 6,943,700
Long-Lived Asset
Expenditures 18,300 900 1,600 - 20,800
Depreciation and
Amortization 76,000 9,800 24,300 - 110,100
Approximately 47% and 46% of net sales of benchtop laboratory equipment
for the three month periods ended September 30, 2015 and 2014, respectively,
were derived from the Company's main product, the Vortex-Genie 2(R) mixer,
excluding accessories.
Approximately 21% and 19% of total benchtop laboratory equipment sales
were derived from the new Torbal Scales Division for the three months
ended September 30, 2015 and 2014, respectively.
For the three months ended September 30, 2015, and 2014, respectively,
two customers accounted in the aggregate for approximately 13% of the
net sales of the Benchtop Laboratory Equipment Operations for each period,
11% and 9% of the Company's revenues. Sales of catalyst research
instruments generally comprise a few very large orders averaging at least
$100,000 per order to a limited number of customers, who differ from order
to order. Sales to one and five customers during the three months ended
September 30, 2015 and 2014, accounted respectively, for approximately
76% and 99% of the Catalyst Research Instrument Operations' revenues
and 8% and 33% of the Company's total revenues.
The Company's foreign sales are principally to customers in Europe
and Asia.
5. Fair Value of Financial Instruments:
The FASB defines the fair value of financial instruments as the amount
that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement
date. Fair value measurements do not include transaction costs.
The accounting guidance also expands the disclosure requirements around
fair value and establishes a fair value hierarchy of valuation inputs.
The hierarchy prioritizes the inputs into three levels based on the extent
to which inputs used in measuring fair value are observable in the market.
Each fair value measurement is reported in one of the three levels, which
is determined by the lowest level input that is significant to the fair
value measurement in its entirety. These levels are described below:
Level 1 Inputs that are based upon unadjusted quoted prices for
identical instruments traded in active markets.
9
Level 2 Quoted prices in markets that are not considered to be
active or financial instruments for which all significant inputs are
observable, either directly or indirectly.
Level 3 Prices or valuation that require inputs that are both
significant to the fair value measurement and unobservable.
The following tables set forth by level within the fair value hierarchy
the Company's financial assets that were accounted for at fair value on a
recurring basis at September 30, 2015 and June 30, 2015 according to the
valuation techniques the Company used to determine their fair values:
Fair Value Measurements Using Inputs
Considered as
Assets:
Fair Value at
September 30, 2015 Level 1 Level 2 Level 3
______________ __________ _______ ________
Cash and cash equivalents $ 530,200 $ 530,200 $ - $ -
Restricted cash 300,000 300,000 - -
Available for sale securities 277,000 277,000 - -
__________ __________ _______ ________
Total $1,107,200 $1,107,200 $ - $ -
========== ========== ======= ========
Liabilities:
Contingent consideration $ 266,200 $ - $ - $266,200
========== ========== ======= ========
Fair Value Measurements Using Inputs
Considered as
Assets:
Fair Value at
June 30, 2015 Level 1 Level 2 Level 3
______________ __________ _______ ________
Cash and cash equivalents $ 482,000 $ 482,000 $ - $ -
Restricted cash 300,000 300,000 - -
Available for sale securities 281,800 281,800 - -
__________ __________ _______ ________
Total $1,063,800 $1,063,800 $ - $ -
========== ========== ======= ========
Liabilities:
Contingent consideration $ 367,100 $ - $ - $367,100
========== ========== ======= ========
Investments in marketable securities classified as available-for-sale by
security type at September 30, 2015 and June 30, 2015 consisted of the
following:
Unrealized
Fair Holding Gain
Cost Value (Loss)
____________ _________ ____________
At September 30, 2015:
Available for sale:
Equity securities $ 29,300 $ 34,000 $ 4,700
Mutual funds 254,800 243,000 ( 11,800)
_________ _________ ___________
$ 284,100 $ 277,000 $ ( 7,100)
========= ========= ===========
10
Unrealized
Fair Holding Gain
Cost Value (Loss)
____________ _________ ____________
At June 30, 2015:
Available for sale:
Equity securities $ 29,300 $ 35,800 $ 6,500
Mutual funds 255,800 246,000 ( 9,800)
__________ _________ __________
$ 285,100 $ 281,800 $ ( 3,300)
========== ========= ==========
6. Inventories:
Inventories for financial statement purposes are based on perpetual
inventory records at September 30, 2015 and based on a physical count as
of June 30, 2015. Components of inventory are as follows:
September 30, June 30,
2015 2015
____________ ___________
Raw materials $1,358,600 $1,420,800
Work in process 652,300 442,900
Finished goods 332,900 350,000
____________ ___________
$2,343,800 $2,213,700
============ ===========
7. Loss per common share:
Basic loss per common share is computed by dividing net loss by the
weighted-average number of shares outstanding. Diluted earnings per
common share include the dilutive effect of stock options, if any.
Loss per common share was computed as follows:
For the Three Month
Periods Ended
September 30,
___________________
2015 2014
____________ _____________
Net loss ($ 60,100) ($ 161,300)
Weighted average common
shares outstanding 1,489,112 1,469,112
========= =========
Weighted average dilutive
common shares outstanding 1,489,112 1,469,112
========= =========
Basic loss per
common share ($ .04) ($ .11)
=========== ===========
Diluted loss per
common share ($ .04) ($ .11)
=========== ===========
11
Approximately 38,500 and 51,000 shares of the Company's Common Stock
issuable upon the exercise of outstanding options were excluded from the
calculation of diluted loss per common share, for the three months ended
September 30, 2015 and 2014, because the effect would be anti-dilutive due
to the loss for each period.
8. Goodwill and Other Intangible Assets:
Goodwill represents the excess of the purchase price over the fair value
of the net assets acquired in connection with the Company's acquisition of
Altamira and SBI's acquisition of assets. Goodwill amounted to $705,300
as of September 30, 2015 and June 30, 2015, all of which is expected to be
deductible for tax purposes.
The components of other intangible assets are as follows:
Useful Accumulated
Lives Cost Amortization Net
________ __________ ____________ _________
At September 30, 2015:
Technology, trademarks 5/10 yrs. $1,215,800 $ 649,400 $ 566,400
Trade names 6 yrs. 140,000 36,900 103,100
Websites 5 yrs. 210,000 66,500 143,500
Customer relationships 9/10 yrs. 357,000 240,900 116,100
Sublicense agreements 10 yrs. 294,000 113,900 180,100
Non-compete agreements 5 yrs. 384,000 196,800 187,200
Intellectual Property, Research
and Development(IPR&D) 3 yrs. 110,000 58,100 51,900
Other intangible assets 5 yrs. 164,100 149,400 14,700
__________ __________ __________
$2,874,900 $1,511,900 $1,363,000
========== ========== ==========
Useful Accumulated
Lives Cost Amortization Net
________ __________ ____________ _________
At June 30, 2015:
Technology, trademarks 5/10 yrs. $1,226,800 $ 624,200 $ 602,600
Trade names 6 yrs. 140,000 31,100 108,900
Websites 5 yrs. 210,000 56,000 154,000
Customer relationships 9/10 yrs. 357,000 236,200 120,800
Sublicense agreements 10 yrs. 294,000 106,600 187,400
Non-compete agreements 5 yrs. 384,000 182,700 201,300
Intellectual Property, Research
and Development(IPR&D) 3 yrs. 110,000 48,900 61,100
Other intangible assets 5 yrs. 164,000 148,200 15,800
__________ __________ __________
$2,885,800 $1,433,900 $1,451,900
========== ========== ==========
Total amortization expense was $86,300 and $88,100 for the three months
ended September 30, 2015 and 2014, respectively. As of September 30, 2015,
estimated future amortization expense related to intangible assets is
$248,100 for the remainder of the fiscal year ending June 30, 2016,
$337,000 for fiscal 2017, $324,000 for fiscal 2018, $246,600 for fiscal
2019, $80,400 for fiscal 2020, and $126,900 thereafter.
12
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis or Plan of Operations
Certain statements contained in this report are not based on historical facts,
but are forward-looking statements that are based upon various assumptions
about future conditions. Actual events in the future could differ materially
from those described in the forward-looking information. Numerous unknown
factors and future events could cause such differences, including but not
limited to, product demand, market acceptance, impact of competition, the
ability to reach final agreements, the ability to finance and produce to
customers' specifications for catalyst research instruments, and to develop
marketable bioprocessing systems, adverse economic conditions, and other
factors affecting the Company's business that are beyond the Company's control.
Consequently, no forward-looking statement can be guaranteed.
We undertake no obligation to publicly update forward-looking
statements, whether as a result of new information, future events or
otherwise.
Liquidity and Capital Resources
_______________________________
Cash and cash equivalents increased by $48,200 to $530,200 as of September 30,
2015 from $482,000 as of June 30, 2015.
Net cash used in operating activities was $44,400 for the three months ended
September 30, 2015 as compared to cash use of $259,700 for the comparable three
month period in 2014, primarily due to a decreased loss and lower accounts
receivable balances. Cash used in investing activities was $6,500 for the
three month period ended September 30, 2015 compared to cash provided of
$54,200 for the three month period ended September 30, 2014 due primarily to
the redemptions of investments in the prior year.
The Company's working capital decreased by $99,900 to $3,311,400 at September
30, 2015 from $3,411,300 at June 30, 2015, mainly as a result of the borrowings
under the line of credit and contingent consideration payments.
The Company has two lines of credit with First National Bank of Pennsylvania -
an Export-Related Revolving Line of Credit which is guaranteed by the Export-
Import Bank of the United States which provides for export-related borrowings
of up to $998,500 bearing interest at prime plus 2% and an annual fee of 1.75%
and a second one-year Demand Line of Credit which provides for borrowings of up
to $300,000 for regular working capital needs, bearing interest at prime,
currently 3.25%, which is collaterized by a cash collateral account of $300,000
which will be released upon certain financial criteria being met or the line
being paid and terminated, which ever comes first. Advances on both lines are
also secured by a pledge of the Company's assets including inventory, accounts,
chattel paper, equipment and general intangibles of the Company. As of
September 30, 2015 $200,000 was outstanding under the Export-Related line and
no borrowings were made under the second line.
Management believes that the Company will be able to meet its cash flow needs
during the next 12 months from its available financial resources which include
its cash and investment securities, lines of credit, and operations.
13
Results of Operations
_____________________
Financial Overview
__________________
The Company incurred a loss of $77,900 before income tax benefit for the three
months ended September 30, 2015 compared to a loss of $222,900 before income
tax benefit for the comparable period last year, the improvement primarily due
to higher sales and margins generated by the Benchtop Laboratory Equipment
Operations which produced income for the segment compared to a loss last year.
The result included non-cash amounts for depreciation and amortization of
$105,200 and $110,100 for the three months ended September 30, 2015 and 2014,
respectively.
The Three Months Ended September 30, 2015 Compared With the Three Months Ended
September 30, 2014
______________________________________________________________________________
Revenues for the three months ended September 30, 2015 decreased by $217,600
(13.1%) to $1,444,500 from $1,662,100 for the three months ended September 30,
2014, primarily as a result of a $398,100 decrease in catalyst research
instrument sales. Sales of benchtop laboratory products increased by $176,600,
result of increased sales of Torbal brand products, and increased sales of
Genie brand products to overseas customers. Catalyst research instruments are
sold pursuant to a small number of larger orders, typically averaging over
$100,000 each, resulting in significant swings in revenues, and the
Bioprocessing Systems Operations' revenues ($28,500) consist primarily of
earned royalties. The backlog of orders for catalyst research instruments was
$2,944,000 as of September 30, 2015, due to a significant order for export,
substantially all of which is expected to be delivered by fiscal year end, as
compared to the backlog as of September 30, 2014 of $439,500.
The gross profit percentage for the three months ended September 30, 2015
increased to 41.2% compared to 30.1% for the three months ended September 30,
2014, primarily due to lower labor and overhead costs for the Benchtop
Laboratory Equipment Operations and the lower gross profit for the Catalyst
Research Instruments Operations due to lower sales by the segment.
General and administrative expenses for the three months ended September 30,
2015 increased by $81,700 (25.0%) to $408,200 from $326,500 for the three
months ended September 30, 2014, primarily due to an increase in expenses
incurred by the Torbal division of the Benchtop Laboratory Equipment
Operations.
Selling expenses for the three months ended September 30, 2015 decreased
$128,300 (43.4%) to $167,000 from $295,300 for the three months ended September
30, 2014, primarily the result of a decrease in sales commissions for the
Catalyst Research Instruments Operations.
Research and development expenses for the three months ended September 30, 2015
decreased by $21,700 (20.3%) to $85,400 from $107,100 for the three months
ended September 30, 2014, due to a reduction in new product development costs
by the Benchtop Laboratory Equipment Operations due to the release of new
product.
For the three months ended September 30, 2015, the income tax benefit was
$17,800 compared to income tax benefit of $61,600 for the three months ended
September 30, 2014 due to the decreased loss for the period.
14
As a result, the net loss for the three months ended September 30, 2015 was
$60,100 compared to a net loss of $161,300 for the three months ended September
30, 2014.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures. As of the end of the period
covered by this report, based on an evaluation of the Company's disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the
Securities Exchange Act of 1934), the Chief Executive and Chief Financial
Officer of the Company has concluded that the Company's disclosure controls and
procedures are effective to ensure that information required to be disclosed by
the Company in its Exchange Act reports is recorded, processed, summarized and
reported within the applicable time periods specified by the SEC's rules and
forms. The Company also concluded that information required to be disclosed in
such reports is accumulated and communicated to the Company's management,
including its principal executive and principal financial officer, as
appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting. There was no change in
the Company's internal controls over financial reporting that occurred during
the most recently completed fiscal quarter that materially affected or is
reasonably likely to materially affect the Company's internal controls over
financial reporting.
15
Part II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibit Number: Description
31.1 Certification of Chief Executive
Officer and Chief Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
32.1 Certification of Chief Executive Officer
and Chief Financial Officer pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
(b) Reports on Form 8-K:
None
16
SCIENTIFIC INDUSTRIES, INC. AND SUBSIDIARIES
SIGNATURE
In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Scientific Industries, Inc.
Registrant
/s/ Helena R. Santos
__________________________________
Helena R. Santos
President, Chief Executive Officer
and Treasurer
Principal Executive, Financial and
Accounting Officer
Date: November 12, 2015
17
EX-32
2
ex32915.txt
CERTIFICATION
Exhibit 31.1
CERTIFICATION
I, Helena R. Santos, certify that:
1. I have reviewed this report on Form 10-Q for the quarter
ended September 30, 2015 of Scientific Industries, Inc., a smaller
reporting company (the "Registrant");
2. Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the Registrant as of, and for, the periods presented in
this report;
4. I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15 (f) and 15d-15(f) for the
Registrant and have:
a) Designed such internal disclosure and procedures, or caused such
controls and procedures to be designed under my supervision, to ensure
that material information relating to the Registrant, including its
consolidated subsidiaries, is made known to me by others within those
entities, particularly during the period in which this report is being
prepared;
b) Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed
under my supervision, to provide reasonable assurance, regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted
accounting principles;
c) Evaluated the effectiveness of the Registrant's disclosure
controls and procedures and presented in this report my conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and
d) Disclosed in this report any change in the Registrant's internal
control over financial reporting that occurred during the Registrant's
most recent fiscal quarter that has materially affected, or is
reasonably likely to affect, the Registrant?s internal control over
financial reporting; and
5. I have disclosed, based on my most recent evaluation of internal
controls over financial reporting, to the Registrant's auditors and
the audit committee of the Registrant's board of directors (or persons
performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which
are reasonably likely to adversely affect the Registrant's ability to
record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrant's
internal controls over financial reporting.
November 12, 2015
/s/ Helena R. Santos
____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer
EX-31
3
ex31915.txt
CERTIFICATION
Exhibit 32.1
CERTIFICATION
The undersigned as Chief Executive Officer and Chief Financial Officer
of the Company, does hereby certify that the foregoing Quarterly Report
of SCIENTIFIC INDUSTRIES, INC. (the "Company"), on Form 10-Q for the
period ended September 30, 2015:
(1) Fully complies with the requirements of Section 13 or
15 (d) of the Securities Exchange Act of 1934; and
(2) Fairly presents, in all material respects, the financial
condition and results of operations of the Company.
November 12, 2015
/s/ Helena R. Santos
____________________
Helena R. Santos
Chief Executive Officer and Chief Financial Officer
A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to
the Securities and Exchange Commission or its staff upon request.
EX-101.INS
4
scnd-20150930.xml
XBRL FILE
0000087802
2015-07-01
2015-09-30
0000087802
2015-09-30
0000087802
2015-06-30
0000087802
SCND:BenchtopLaboratoryEquipmentMember
2015-07-01
2015-09-30
0000087802
SCND:BenchtopLaboratoryEquipmentMember
2014-07-01
2014-09-30
0000087802
SCND:CatalystResearchInstrumentsMember
2015-07-01
2015-09-30
0000087802
SCND:CatalystResearchInstrumentsMember
2014-07-01
2014-09-30
0000087802
SCND:BioprocessingSystemsMember
2015-07-01
2015-09-30
0000087802
SCND:BioprocessingSystemsMember
2014-07-01
2014-09-30
0000087802
us-gaap:CorporateAndOtherMember
2015-07-01
2015-09-30
0000087802
us-gaap:CorporateAndOtherMember
2014-07-01
2014-09-30
0000087802
us-gaap:ConsolidatedEntitiesMember
2015-07-01
2015-09-30
0000087802
us-gaap:ConsolidatedEntitiesMember
2014-07-01
2014-09-30
0000087802
us-gaap:FairValueInputsLevel1Member
2015-09-30
0000087802
us-gaap:FairValueInputsLevel1Member
2015-06-30
0000087802
us-gaap:FairValueInputsLevel2Member
2015-09-30
0000087802
us-gaap:FairValueInputsLevel2Member
2015-06-30
0000087802
us-gaap:FairValueInputsLevel3Member
2015-09-30
0000087802
us-gaap:FairValueInputsLevel3Member
2015-06-30
0000087802
SCND:MutualFundsMember
2015-09-30
0000087802
SCND:MutualFundsMember
2015-06-30
0000087802
us-gaap:EquitySecuritiesMember
2015-09-30
0000087802
us-gaap:EquitySecuritiesMember
2015-06-30
0000087802
us-gaap:TrademarksMember
2015-09-30
0000087802
us-gaap:TrademarksMember
2015-06-30
0000087802
us-gaap:CustomerRelationshipsMember
2015-09-30
0000087802
us-gaap:CustomerRelationshipsMember
2015-06-30
0000087802
us-gaap:LicensingAgreementsMember
2015-09-30
0000087802
us-gaap:LicensingAgreementsMember
2015-06-30
0000087802
us-gaap:ContractualRightsMember
2015-09-30
0000087802
us-gaap:ContractualRightsMember
2015-06-30
0000087802
us-gaap:OtherIntangibleAssetsMember
2015-09-30
0000087802
us-gaap:OtherIntangibleAssetsMember
2015-06-30
0000087802
2014-07-01
2014-09-30
0000087802
2014-06-30
0000087802
SCND:TwoCustomersMember
SCND:BenchtopLaboratoryEquipmentMember
2015-07-01
2015-09-30
0000087802
SCND:TwoCustomersMember
SCND:BenchtopLaboratoryEquipmentMember
2014-07-01
2014-09-30
0000087802
SCND:OneCustomerMember
SCND:CatalystResearchInstrumentsMember
2015-07-01
2015-09-30
0000087802
us-gaap:TradeNamesMember
2015-09-30
0000087802
SCND:WebsitesMember
2015-09-30
0000087802
SCND:IPRandDMember
2015-09-30
0000087802
us-gaap:TrademarksMember
2015-07-01
2015-09-30
0000087802
us-gaap:TrademarksMember
2014-07-01
2015-06-30
0000087802
us-gaap:TradeNamesMember
2015-07-01
2015-09-30
0000087802
us-gaap:TradeNamesMember
2014-07-01
2015-06-30
0000087802
SCND:WebsitesMember
2015-07-01
2015-09-30
0000087802
SCND:WebsitesMember
2014-07-01
2015-06-30
0000087802
us-gaap:CustomerRelationshipsMember
2015-07-01
2015-09-30
0000087802
us-gaap:CustomerRelationshipsMember
2014-07-01
2015-06-30
0000087802
us-gaap:LicensingAgreementsMember
2015-07-01
2015-09-30
0000087802
us-gaap:LicensingAgreementsMember
2014-07-01
2015-06-30
0000087802
us-gaap:ContractualRightsMember
2015-07-01
2015-09-30
0000087802
us-gaap:ContractualRightsMember
2014-07-01
2015-06-30
0000087802
SCND:IPRandDMember
2015-07-01
2015-09-30
0000087802
SCND:IPRandDMember
2014-07-01
2015-06-30
0000087802
us-gaap:OtherIntangibleAssetsMember
2015-07-01
2015-09-30
0000087802
us-gaap:OtherIntangibleAssetsMember
2014-07-01
2015-06-30
0000087802
2014-09-30
0000087802
us-gaap:TradeNamesMember
2015-06-30
0000087802
SCND:WebsitesMember
2015-06-30
0000087802
SCND:IPRandDMember
2015-06-30
0000087802
2015-10-30
0000087802
SCND:FiveCustomersAndOneCustomerMember
SCND:CatalystResearchInstrumentsMember
2014-07-01
2014-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
SCIENTIFIC INDUSTRIES INC
0000087802
10-Q
2015-09-30
false
--06-30
No
No
Yes
Smaller Reporting Company
Q1
2016
0.05
0.05
7000000
7000000
1489112
530200
482000
530200
482000
0
0
0
0
493700
388100
277000
281800
277000
281800
0
0
0
0
737400
1081700
2343800
2213700
145300
68600
118000
114200
4451700
4542000
300000
300000
300000
300000
0
0
0
0
222800
235200
1363000
1451900
566400
602600
116100
120800
180100
187400
187200
201300
14700
15800
103100
143500
51900
108900
154000
61100
705300
705300
52500
52500
169400
154500
6964700
7141400
201100
227600
93500
76400
200000
0
200000
200000
316800
519900
128900
106800
1140300
1130700
137300
260300
1277600
1391000
75400
75400
2487300
2486700
-7100
-3300
3183900
3244000
5739500
5802800
52400
52400
5687100
5750400
6964700
7141400
19802
19802
1508914
1508914
1508914
1508914
1444500
1662100
849400
1161900
595100
500200
408200
326500
167000
295300
85400
107100
660600
728900
-65500
-228700
400
800
-4700
6200
8100
1200
-12400
5800
-77900
-222900
0
-57200
-17800
-4400
-17800
-61600
-60100
-161300
-.04
-.11
-.04
-.11
-3800
-700
-63900
-162000
0
-1300
105200
73800
76000
6900
9800
24500
24300
0
0
105200
110100
110100
600
1000
0
-4900
-344300
38500
130100
-26300
76700
61600
-26500
-31500
17100
3300
-203100
-83900
15700
-98400
-44400
-259700
0
75000
6500
19700
0
1100
-6500
54200
200000
200000
-100900
-98900
0
18800
0
20000
99100
99900
48200
-105600
18500
3500
4400
1200
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Principles of consolidation:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying consolidated financial statements include
the accounts of Scientific Industries, Inc. (“Scientific”, a Delaware corporation), Altamira Instruments, Inc.(“Altamira”,
a wholly owned subsidiary and Delaware corporation), Scientific Packaging Industries, Inc. (an inactive wholly owned subsidiary
and New York corporation) and Scientific Bioprocessing, Inc., (“SBI”, a wholly owned subsidiary and Delaware corporation).
All are collectively referred to as the “Company”. All material intercompany balances and transactions have been eliminated.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 0pt; text-align: left; text-indent: 0pt">In May 2014, the FASB issued ASU 2014-09, Revenue from
Contracts with Customers amending revenue recognition requirements for multiple-deliverable revenue arrangements. This update provides
guidance on how revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the entity expects to be entitled in exchange for the goods or services. This determination is made
in five steps: (i) identify the contract with the customer: (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred the effective date to fiscal years
beginning after December 15, 2018, or the Company's fiscal year ending June 30, 2020, and early adoption of the standard is permitted,
but not before the original effective date of December 15, 2017. The Company is evaluating the effect this guidance will have on
the consolidated financial statements and related disclosures.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: left">In June 2014, the FASB issued ASU 2014-12, Compensation –
Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target
Could be Achieved After the Requisite Service Period. This update affects reporting entities that grant their employee’s
targets that affects vesting could be achieved after the requisite service period. The new standard requires that a performance
target that affects vesting and that could be achieved after the requisite services period be treated as a performance condition.
The new standard will be effective for the Company beginning July 1, 2016, and early adoption is permitted. The Company expects
the adoption will not have a material impact on its financial condition, results of operations or cash flows.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: left">In July 2015, the FASB issued ASU
No. 2015-11, "Inventory: Simplifying the Measurement of Inventory", that requires inventory not measured using either
the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value. Net
realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable cost of completion,
disposal and transportation. The new standard will be effective for fiscal years beginning after December 15, 2016, including
interim periods within those fiscal years, and will be applied prospectively. Early adoption is permitted. The Company is evaluating
the impact that this standard will have on its consolidated financial statements.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"><font style="letter-spacing: -0.15pt">On February 26, 2014,
the Company acquired substantially all the assets of a </font>privately owned company consisting principally of inventory, fixed
assets, and intangible assets related to the production and sale of a variety of laboratory and pharmacy balances and scales.
The acquisition was pursuant to an asset purchase agreement whereby the Company paid the sellers $700,000 in cash, 126,449 shares
of Common Stock valued at $427,500 and agreed to make additional cash payments based on a percentage of net sales of the business
acquired equal to 8% for the period ending June 30, 2014 annualized, 9% for the year ending June 30, 2015, 10% for the year ending
June 30, 2016 and 11% for the year ending June 30, 2017, estimated at a present value of $460,000 on the date of acquisition.
Payments related to this contingent consideration for each period are due in September following the fiscal year. Contingent consideration
payments made amounted to $100,900 and $98,900 during the three months ended September 30, 2015 and 2014, respectively.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"><font style="letter-spacing: -0.15pt"> </font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"><font style="letter-spacing: -0.15pt"> The products,
which are similar to the Company’s other Benchtop Laboratory Equipment, and in many cases used by the same customers, are
marketed under the Torbal® brand. The principal customers are pharmacies, pharmacy schools, universities, government laboratories,
and industries utilizing a precision scale. The products are sold primarily on a direct basis, including through </font>the Company’s
e-commerce site.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 0pt">Management of the Company allocated the purchase price
based on its valuation of the assets acquired, as follows:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 1in"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 63%"> </td>
<td style="width: 20%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Curent Assets</td>
<td style="text-align: right"> $                  144,000</td></tr>
<tr style="vertical-align: bottom">
<td>Property, Plant & Equipment</td>
<td style="text-align: right">                     118,100</td></tr>
<tr style="vertical-align: bottom">
<td>Goodwill</td>
<td style="text-align: right">                     115,400</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Other Intangible Assets</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                  1,210,000</td></tr>
<tr style="vertical-align: bottom">
<td>Total Purchase Price</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $               1,587,500</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 1in"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 22.3pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt -40pt; text-indent: 54.2pt">*See Note 8, “Goodwill and
Other Intangible Assets”.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 22.3pt; text-indent: 54.2pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 0pt">Of the $1,210,000 of the acquired other intangible assets,
$570,000 was assigned to technology and websites with a useful life of 5 years, $120,000 was assigned to customer relationships
with an estimated useful life of 9 years, $140,000 was assigned to the trade name with an estimated useful life of 6 years, $110,000
was assigned to the IPR&D with an estimated useful life of 3 years, and $270,000 was assigned to non-compete agreements with
an estimated useful life of 5 years.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 0pt">In connection with the acquisition, the Company entered
into a three-year employment agreement with the previous Chief Operating Officer of the acquired business as President of the Company’s
new Torbal Division and Director of Marketing for the Company. The agreement may be extended by mutual consent for an additional
two years.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company views its operations as
three segments: the manufacture and marketing of standard benchtop laboratory equipment including the balances and scales by its
Torbal Scales Division for research in university, hospital and industrial laboratories sold primarily through laboratory equipment
distributors and on a direct basis (“Benchtop Laboratory Equipment”), the manufacture and marketing of custom-made
catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct
basis (“Catalyst Research Instruments”) and the marketing and production of bioprocessing systems for laboratory research
in the biotechnology industry sold directly to customers and through distributors (“Bioprocessing Systems”).</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 34%"> </td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Benchtop Laboratory Equipment</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Catalyst Research Instruments</td>
<td style="border-bottom: Black 0.5pt solid; width: 14%; text-align: right">Bioprocessing Systems</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Corporate and Other</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Consolidated</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Three months ended September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Revenues</td>
<td style="text-align: right"> $               1,263,000</td>
<td style="text-align: right"> $                  153,000</td>
<td style="text-align: right"> $                       28,500</td>
<td style="text-align: right"> $                           -   </td>
<td style="text-align: right"> $               1,444,500</td></tr>
<tr style="vertical-align: bottom">
<td>Foreign Sales</td>
<td style="text-align: right">                     599,000</td>
<td style="text-align: right">                         7,800</td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     606,800</td></tr>
<tr style="vertical-align: bottom">
<td>Income (Loss) from Operations</td>
<td style="text-align: right">                       54,700</td>
<td style="text-align: right">                     (82,000)</td>
<td style="text-align: right">                        (30,100)</td>
<td style="text-align: right">                       (8,100)</td>
<td style="text-align: right">                     (65,500)</td></tr>
<tr style="vertical-align: bottom">
<td>Assets</td>
<td style="text-align: right">                  4,056,400</td>
<td style="text-align: right">                  1,613,200</td>
<td style="text-align: right">                        730,700</td>
<td style="text-align: right">                     564,400</td>
<td style="text-align: right">                  6,964,700</td></tr>
<tr style="vertical-align: bottom">
<td>Long-Lived Asset Expenditures</td>
<td style="text-align: right">                         6,500</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                         6,500</td></tr>
<tr style="vertical-align: bottom">
<td>Depreciation and Amortization </td>
<td style="text-align: right">                       73,800</td>
<td style="text-align: right">                         6,900</td>
<td style="text-align: right">                          24,500</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     105,200</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Segment information is reported as follows:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 34%"> </td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Benchtop Laboratory Equipment</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Catalyst Research Instruments</td>
<td style="border-bottom: Black 0.5pt solid; width: 14%; text-align: right">Bioprocessing Systems</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Corporate and Other</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Consolidated</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Three months ended September 30, 2014:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Revenues</td>
<td style="text-align: right"> $               1,086,400</td>
<td style="text-align: right"> $                  551,100</td>
<td style="text-align: right"> $                       24,600</td>
<td style="text-align: right"> $                           -   </td>
<td style="text-align: right"> $               1,662,100</td></tr>
<tr style="vertical-align: bottom">
<td>Foreign Sales</td>
<td style="text-align: right">                     411,100</td>
<td style="text-align: right">                     443,500</td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     854,600</td></tr>
<tr style="vertical-align: bottom">
<td>Loss from Operations</td>
<td style="text-align: right">                   (118,100)</td>
<td style="text-align: right">                     (70,200)</td>
<td style="text-align: right">                        (40,400)</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                   (228,700)</td></tr>
<tr style="vertical-align: bottom">
<td>Assets</td>
<td style="text-align: right">                  4,074,800</td>
<td style="text-align: right">                  1,507,400</td>
<td style="text-align: right">                        786,600</td>
<td style="text-align: right">                     574,900</td>
<td style="text-align: right">                  6,943,700</td></tr>
<tr style="vertical-align: bottom">
<td>Long-Lived Asset Expenditures</td>
<td style="text-align: right">                       18,300</td>
<td style="text-align: right">                            900</td>
<td style="text-align: right">                            1,600</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                       20,800</td></tr>
<tr style="vertical-align: bottom">
<td>Depreciation and Amortization </td>
<td style="text-align: right">                       76,000</td>
<td style="text-align: right">                         9,800</td>
<td style="text-align: right">                          24,300</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     110,100</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">Approximately 47% and 46% of net sales of benchtop laboratory
equipment for the three month periods ended September 30, 2015 and 2014, respectively, were derived from the Company’s main
product, the Vortex-Genie 2® mixer, excluding accessories.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">Approximately 21% and 19% of total benchtop laboratory
equipment sales were derived from the new Torbal Scales Division for the three months ended September 30, 2015 and 2014, respectively.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">For the three months ended September 30, 2015, and 2014,
respectively, two customers accounted in the aggregate for approximately 13% of the net sales of the Benchtop Laboratory Equipment
Operations for each period, 11% and 9% of the Company’s revenues. Sales of catalyst research instruments generally comprise
a few very large orders averaging at least $100,000 per order to a limited number of customers, who differ from order to order.
Sales to one and five customers during the three months ended September 30, 2015 and 2014, accounted respectively, for approximately
76% and 99% of the Catalyst Research Instrument Operations’ revenues and 8% and 33% of the Company’s total revenues.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">The Company’s foreign sales are principally to customers in Europe and Asia.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">The FASB defines the fair value of financial instruments
as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. Fair value measurements do not include transaction costs.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">The accounting guidance also expands the disclosure requirements
around fair value and establishes a fair value hierarchy of valuation inputs. The hierarchy prioritizes the inputs into three levels
based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported
in one of the three levels, which is determined by the lowest level input that is significant to the fair value measurement in
its entirety. These levels are described below:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-indent: -94.5pt">	Level 1	Inputs that are based
upon unadjusted quoted prices for identical instruments traded in active markets.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-align: center"></p>
<p style="font: 8pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">	</p>
<p style="font: 8pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt"><font style="font: 8pt Times New Roman, Times, Serif">Level
2	Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are
observable either directly or indirectly.</font></p> <p style="font: 10pt Sans Serif 12cpi; margin: 0; text-indent: 0.5in"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 94.5pt; text-indent: -94.5pt">Level 3 Prices or valuation that
require inputs that are both significant to the fair value measurement and unobservable.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following tables set forth by level within the fair value hierarchy
the Company’s financial assets that were accounted for at fair value on a recurring basis at September 30, 2015 and June
30, 2015 according to the valuation techniques the Company used to determine their fair values:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="margin: 0pt"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: middle">
<td> </td>
<td colspan="2">Fair Value Measurements Using Inputs Considered as</td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td style="width: 20%">Assets:</td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="border-bottom: black 0.5pt solid; text-align: center">Fair Value at September 30, 2015</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 1</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 2</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 3</td></tr>
<tr style="vertical-align: middle">
<td>Cash and cash equivalents</td>
<td style="text-align: right"> $                                    530,200</td>
<td style="text-align: right"> $                    530,200</td>
<td style="text-align: right"> $                        -   </td>
<td style="text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td>Restricted cash</td>
<td style="text-align: right">                                       300,000</td>
<td style="text-align: right">                       300,000</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td style="padding-bottom: 1pt">Available for sale securities</td>
<td style="border-bottom: black 1pt solid; text-align: right">                                       277,000</td>
<td style="border-bottom: black 1pt solid; text-align: right">                       277,000</td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt">                           -   </td>
<td style="border-bottom: black 1pt solid; text-align: right">                               -   </td></tr>
<tr style="vertical-align: middle">
<td>Total</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                 1,107,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                 1,107,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td>Liabilities:</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td> Contingent consideration</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                    266,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                              -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                   266,200</td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="text-align: right"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td colspan="2">Fair Value Measurements Using Inputs Considered as</td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td>Assets:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="border-bottom: black 0.5pt solid; text-align: center">Fair Value at June 30, 2015</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 1</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 2</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 3</td></tr>
<tr style="vertical-align: middle">
<td>Cash and cash equivalents</td>
<td style="text-align: right"> $                                    482,000</td>
<td style="text-align: right"> $                    482,000</td>
<td style="text-align: right"> $                        -   </td>
<td style="text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td>Restricted Cash</td>
<td style="text-align: right">                                       300,000</td>
<td style="text-align: right">                       300,000</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td style="padding-bottom: 1pt">Available for sale securities</td>
<td style="border-bottom: black 1pt solid; text-align: right">                                       281,800</td>
<td style="border-bottom: black 1pt solid; text-align: right">                       281,800</td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt">                           -   </td>
<td style="border-bottom: black 1pt solid; text-align: right">                               -   </td></tr>
<tr style="vertical-align: middle">
<td>Total</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                 1,063,800</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                 1,063,800</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td>Liabilities:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> Contingent consideration</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                    367,100</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                              -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                   367,100</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Investments in marketable securities classified as available-for-sale by security type at September 30, 2015
and June 30, 2015 consisted of the following:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 42%"> </td>
<td style="border-bottom: Black 0.5pt solid; width: 25%; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; width: 18%; text-align: right">Fair Value</td>
<td style="border-bottom: Black 0.5pt solid; width: 15%; text-align: right">Unrealized Holding Gain (Loss)</td></tr>
<tr style="vertical-align: bottom">
<td>At September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Available for sale:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Equity securities</td>
<td style="text-align: right"> $                                      29,300</td>
<td style="text-align: right"> $                      34,000</td>
<td style="text-align: right"> $                  4,700</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">  Mutual funds</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                                       254,800</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                       243,000</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                  (11,800)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                                    284,100</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                    277,000</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                 (7,100)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Fair Value</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Unrealized Holding Gain (Loss)</td></tr>
<tr style="vertical-align: bottom">
<td>At June 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Available for sale:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Equity securities</td>
<td style="text-align: right"> $                                      29,300</td>
<td style="text-align: right"> $                      35,800</td>
<td style="text-align: right"> $                  6,500</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">  Mutual funds</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                                       255,800</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                       246,000</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                    (9,800)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                                    285,100</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                    281,800</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                 (3,300)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>
<p style="font: 8pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">Inventories for financial statement purposes are based
on perpetual inventory records at September 30, 2015 and based on a physical count as of June 30, 2015. Components of inventory
are as follows:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 38%"> </td>
<td style="width: 31%"> </td>
<td style="width: 31%"> </td></tr>
<tr>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: middle; border-bottom: Black 0.5pt solid; text-align: right">September 30, 2015</td>
<td style="vertical-align: middle; border-bottom: Black 0.5pt solid; text-align: right">June 30, 2015</td></tr>
<tr style="vertical-align: bottom">
<td>Raw materials</td>
<td style="text-align: right"> $                     1,358,600</td>
<td style="text-align: right"> $                    1,420,800</td></tr>
<tr style="vertical-align: bottom">
<td>Work in process</td>
<td style="text-align: right">                           652,300</td>
<td style="text-align: right">                          442,900</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Finished goods</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                           332,900</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                          350,000</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $                     2,343,800</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $                    2,213,700</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">Basic loss per common share is computed by dividing net
loss by the weighted-average number of shares outstanding. Diluted earnings per common share include the dilutive effect of stock
options, if any.	</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">Loss per common share was computed as follows:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 66%">Loss per common share was computed as follows:</td>
<td style="width: 17%"> </td>
<td style="width: 17%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td>For the Three Month</td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td>Periods Ended</td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid">September 30, </td>
<td style="border-bottom: Black 0.5pt solid"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">2015</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">2014</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Net loss</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                  (60,100)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                (161,300)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Weighted average common shares outstanding</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                 1,489,112</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                 1,469,112</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Weighted average dilutive common shares outstanding</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">                 1,489,112</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">                 1,469,112</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Basic loss per common share</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.04)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.11)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Diluted loss per common share</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.04)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.11)</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">Approximately 38,500 and 51,000 shares of the Company's
Common Stock issuable upon the exercise of outstanding options were excluded from the calculation of diluted loss per common share,
for the three months ended September 30, 2015 and 2014, because the effect would be anti-dilutive due to the loss for each period.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><font style="background-color: white">Goodwill
represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company's acquisition
of Altamira and SBI’s acquisition of assets. Goodwill amounted to $705,300 as of September 30, 2015 and June 30, 2015, all
of which is expected to be deductible for tax purposes.</font></p>
<p style="font: 10pt Sans Serif 12cpi; margin: 0 0 0 16.5pt; text-indent: 0.5in"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt">The components of other intangible
assets are as follows:</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 55%">The components of other intangible assets are as follows:</td>
<td style="width: 9%"> </td>
<td style="width: 12%"> </td>
<td style="width: 12%"> </td>
<td style="width: 12%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid">Useful Lives</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Accumulated Amortization</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Net</td></tr>
<tr style="vertical-align: bottom">
<td>At September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Technology, trademarks</td>
<td>5/10 yrs.</td>
<td style="text-align: right"> $                 1,215,800</td>
<td style="text-align: right"> $                    649,400</td>
<td style="text-align: right"> $                    566,400</td></tr>
<tr style="vertical-align: bottom">
<td>Trade names</td>
<td>6 yrs.</td>
<td style="text-align: right">                       140,000</td>
<td style="text-align: right">                         36,900</td>
<td style="text-align: right">103,100</td></tr>
<tr style="vertical-align: bottom">
<td>Websites</td>
<td>5 yrs.</td>
<td style="text-align: right">                       210,000</td>
<td style="text-align: right">                         66,500</td>
<td style="text-align: right">143,500</td></tr>
<tr style="vertical-align: bottom">
<td>Customer relationships</td>
<td>9/10 yrs.</td>
<td style="text-align: right">                       357,000</td>
<td style="text-align: right">                       240,900</td>
<td style="text-align: right">116,100</td></tr>
<tr style="vertical-align: bottom">
<td>Sublicense agreements</td>
<td>10 yrs.</td>
<td style="text-align: right">                       294,000</td>
<td style="text-align: right">                       113,900</td>
<td style="text-align: right">180,100</td></tr>
<tr style="vertical-align: bottom">
<td>Non-compete agreements</td>
<td>5 yrs.</td>
<td style="text-align: right">                       384,000</td>
<td style="text-align: right">                       196,800</td>
<td style="text-align: right">187,200</td></tr>
<tr style="vertical-align: bottom">
<td>Intellectual Property, Research and Development (IPR&D)</td>
<td>3 yrs.</td>
<td style="text-align: right">                       110,000</td>
<td style="text-align: right">                         58,100</td>
<td style="text-align: right">51,900</td></tr>
<tr style="vertical-align: bottom">
<td>Other intangible assets</td>
<td>5 yrs.</td>
<td style="text-align: right">                       164,100</td>
<td style="text-align: right">                       149,400</td>
<td style="text-align: right">14,700</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 2.5pt"> </td>
<td style="padding-bottom: 2.5pt"> </td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"> $                 2,874,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"> $                 1,511,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"> $                 1,363,000</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid">Useful Lives</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Accumulated Amortization</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Net</td></tr>
<tr style="vertical-align: bottom">
<td>At June 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Technology,  trademarks</td>
<td>5/10 yrs.</td>
<td style="text-align: right"> $                 1,226,800</td>
<td style="text-align: right"> $                    624,200</td>
<td style="text-align: right"> $                    602,600</td></tr>
<tr style="vertical-align: bottom">
<td>Trade names</td>
<td>6 yrs.</td>
<td style="text-align: right">                       140,000</td>
<td style="text-align: right">                         31,100</td>
<td style="text-align: right">                       108,900</td></tr>
<tr style="vertical-align: bottom">
<td>Websites</td>
<td>5 yrs.</td>
<td style="text-align: right">                       210,000</td>
<td style="text-align: right">                         56,000</td>
<td style="text-align: right">                       154,000</td></tr>
<tr style="vertical-align: bottom">
<td>Customer relationships</td>
<td>10 yrs.</td>
<td style="text-align: right">                       357,000</td>
<td style="text-align: right">                       236,200</td>
<td style="text-align: right">                       120,800</td></tr>
<tr style="vertical-align: bottom">
<td>Sublicense agreements</td>
<td>10 yrs.</td>
<td style="text-align: right">                       294,000</td>
<td style="text-align: right">                       106,600</td>
<td style="text-align: right">                       187,400</td></tr>
<tr style="vertical-align: bottom">
<td>Non-compete agreements</td>
<td>5 yrs.</td>
<td style="text-align: right">                       384,000</td>
<td style="text-align: right">                       182,700</td>
<td style="text-align: right">                       201,300</td></tr>
<tr style="vertical-align: bottom">
<td>Intellectual Property, Research and Development (IPR&D)</td>
<td>3 yrs.</td>
<td style="text-align: right">                       110,000</td>
<td style="text-align: right">                         48,900</td>
<td style="text-align: right">                         61,100</td></tr>
<tr style="vertical-align: bottom">
<td>Other intangible assets</td>
<td>5 yrs.</td>
<td style="text-align: right">                       164,000</td>
<td style="text-align: right">                       148,200</td>
<td style="text-align: right">                         15,800</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 2,885,800</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,433,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,451,900</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">Total amortization
expense was $86,300 and $88,100 for the three months ended September 30, 2015 and 2014, respectively. As of September 30, 2015,
estimated future amortization expense related to intangible assets is $248,100 for the remainder of the fiscal year ending June
30, 2016, $337,000 for fiscal 2017, $324,000 for fiscal 2018, $246,600 for fiscal 2019, $80,400 for fiscal 2020, and $126,900
thereafter.</font></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -60pt; text-indent: 60pt"></p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The accompanying consolidated financial
statements include the accounts of Scientific Industries, Inc. (“Scientific”, a Delaware corporation), Altamira Instruments,
Inc.(“Altamira”, a wholly owned subsidiary and Delaware corporation), Scientific Packaging Industries, Inc. (an inactive
wholly owned subsidiary and New York corporation) and Scientific Bioprocessing, Inc., (“SBI”, a wholly owned subsidiary
and Delaware corporation). All are collectively referred to as the “Company”. All material intercompany balances and
transactions have been eliminated.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 6pt 0pt; text-align: left; text-indent: 0pt">In May 2014, the FASB issued ASU 2014-09, Revenue from
Contracts with Customers amending revenue recognition requirements for multiple-deliverable revenue arrangements. This update provides
guidance on how revenue is recognized to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the entity expects to be entitled in exchange for the goods or services. This determination is made
in five steps: (i) identify the contract with the customer: (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation. In July 2015, the FASB deferred the effective date to fiscal years
beginning after December 15, 2018, or the Company's fiscal year ending June 30, 2020, and early adoption of the standard is permitted,
but not before the original effective date of December 15, 2017. The Company is evaluating the effect this guidance will have on
the consolidated financial statements and related disclosures.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: left">In June 2014, the FASB issued ASU 2014-12, Compensation –
Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target
Could be Achieved After the Requisite Service Period. This update affects reporting entities that grant their employee’s
targets that affects vesting could be achieved after the requisite service period. The new standard requires that a performance
target that affects vesting and that could be achieved after the requisite services period be treated as a performance condition.
The new standard will be effective for the Company beginning July 1, 2016, and early adoption is permitted. The Company expects
the adoption will not have a material impact on its financial condition, results of operations or cash flows.</p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: left"> </p>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: left">In July 2015, the FASB issued ASU
No. 2015-11, "Inventory: Simplifying the Measurement of Inventory", that requires inventory not measured using either
the last in, first out (LIFO) or the retail inventory method to be measured at the lower of cost and net realizable value. Net
realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable cost of completion,
disposal and transportation. The new standard will be effective for fiscal years beginning after December 15, 2016, including
interim periods within those fiscal years, and will be applied prospectively. Early adoption is permitted. The Company is evaluating
the impact that this standard will have on its consolidated financial statements.</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 63%"> </td>
<td style="width: 20%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Curent Assets</td>
<td style="text-align: right"> $                  144,000</td></tr>
<tr style="vertical-align: bottom">
<td>Property, Plant & Equipment</td>
<td style="text-align: right">                     118,100</td></tr>
<tr style="vertical-align: bottom">
<td>Goodwill</td>
<td style="text-align: right">                     115,400</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Other Intangible Assets</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                  1,210,000</td></tr>
<tr style="vertical-align: bottom">
<td>Total Purchase Price</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $               1,587,500</td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 34%"> </td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Benchtop Laboratory Equipment</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Catalyst Research Instruments</td>
<td style="border-bottom: Black 0.5pt solid; width: 14%; text-align: right">Bioprocessing Systems</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Corporate and Other</td>
<td style="border-bottom: Black 0.5pt solid; width: 13%; text-align: right">Consolidated</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Three months ended September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Revenues</td>
<td style="text-align: right"> $               1,263,000</td>
<td style="text-align: right"> $                  153,000</td>
<td style="text-align: right"> $                       28,500</td>
<td style="text-align: right"> $                           -   </td>
<td style="text-align: right"> $               1,444,500</td></tr>
<tr style="vertical-align: bottom">
<td>Foreign Sales</td>
<td style="text-align: right">                     599,000</td>
<td style="text-align: right">                         7,800</td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     606,800</td></tr>
<tr style="vertical-align: bottom">
<td>Income (Loss) from Operations</td>
<td style="text-align: right">                       54,700</td>
<td style="text-align: right">                     (82,000)</td>
<td style="text-align: right">                        (30,100)</td>
<td style="text-align: right">                       (8,100)</td>
<td style="text-align: right">                     (65,500)</td></tr>
<tr style="vertical-align: bottom">
<td>Assets</td>
<td style="text-align: right">                  4,056,400</td>
<td style="text-align: right">                  1,613,200</td>
<td style="text-align: right">                        730,700</td>
<td style="text-align: right">                     564,400</td>
<td style="text-align: right">                  6,964,700</td></tr>
<tr style="vertical-align: bottom">
<td>Long-Lived Asset Expenditures</td>
<td style="text-align: right">                         6,500</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                         6,500</td></tr>
<tr style="vertical-align: bottom">
<td>Depreciation and Amortization </td>
<td style="text-align: right">                       73,800</td>
<td style="text-align: right">                         6,900</td>
<td style="text-align: right">                          24,500</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     105,200</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Benchtop Laboratory Equipment</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Catalyst Research Instruments</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Bioprocessing Systems</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Corporate and Other</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Consolidated</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Three months ended September 30, 2014:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Revenues</td>
<td style="text-align: right"> $               1,086,400</td>
<td style="text-align: right"> $                  551,100</td>
<td style="text-align: right"> $                       24,600</td>
<td style="text-align: right"> $                           -   </td>
<td style="text-align: right"> $               1,662,100</td></tr>
<tr style="vertical-align: bottom">
<td>Foreign Sales</td>
<td style="text-align: right">                     411,100</td>
<td style="text-align: right">                     443,500</td>
<td style="text-align: right">                                  -   </td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     854,600</td></tr>
<tr style="vertical-align: bottom">
<td>Loss from Operations</td>
<td style="text-align: right">                   (118,100)</td>
<td style="text-align: right">                     (70,200)</td>
<td style="text-align: right">                        (40,400)</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                   (228,700)</td></tr>
<tr style="vertical-align: bottom">
<td>Assets</td>
<td style="text-align: right">                  4,074,800</td>
<td style="text-align: right">                  1,507,400</td>
<td style="text-align: right">                        786,600</td>
<td style="text-align: right">                     574,900</td>
<td style="text-align: right">                  6,943,700</td></tr>
<tr style="vertical-align: bottom">
<td>Long-Lived Asset Expenditures</td>
<td style="text-align: right">                       18,300</td>
<td style="text-align: right">                            900</td>
<td style="text-align: right">                            1,600</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                       20,800</td></tr>
<tr style="vertical-align: bottom">
<td>Depreciation and Amortization </td>
<td style="text-align: right">                       76,000</td>
<td style="text-align: right">                         9,800</td>
<td style="text-align: right">                          24,300</td>
<td style="text-align: right">                              -   </td>
<td style="text-align: right">                     110,100</td></tr>
</table>
<p style="margin: 0pt"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: middle">
<td> </td>
<td colspan="2">Fair Value Measurements Using Inputs Considered as</td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td style="width: 20%">Assets:</td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td>
<td style="width: 20%"> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="border-bottom: black 0.5pt solid; text-align: center">Fair Value at September 30, 2015</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 1</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 2</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 3</td></tr>
<tr style="vertical-align: middle">
<td>Cash and cash equivalents</td>
<td style="text-align: right"> $                                    530,200</td>
<td style="text-align: right"> $                    530,200</td>
<td style="text-align: right"> $                        -   </td>
<td style="text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td>Restricted cash</td>
<td style="text-align: right">                                       300,000</td>
<td style="text-align: right">                       300,000</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td style="padding-bottom: 1pt">Available for sale securities</td>
<td style="border-bottom: black 1pt solid; text-align: right">                                       277,000</td>
<td style="border-bottom: black 1pt solid; text-align: right">                       277,000</td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt">                           -   </td>
<td style="border-bottom: black 1pt solid; text-align: right">                               -   </td></tr>
<tr style="vertical-align: middle">
<td>Total</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                 1,107,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                 1,107,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td>Liabilities:</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td> Contingent consideration</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                    266,200</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                              -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                   266,200</td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="text-align: right"> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td colspan="2">Fair Value Measurements Using Inputs Considered as</td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td>Assets:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td style="border-bottom: black 0.5pt solid; text-align: center">Fair Value at June 30, 2015</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 1</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 2</td>
<td style="border-bottom: black 0.5pt solid; text-align: right">Level 3</td></tr>
<tr style="vertical-align: middle">
<td>Cash and cash equivalents</td>
<td style="text-align: right"> $                                    482,000</td>
<td style="text-align: right"> $                    482,000</td>
<td style="text-align: right"> $                        -   </td>
<td style="text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td>Restricted Cash</td>
<td style="text-align: right">                                       300,000</td>
<td style="text-align: right">                       300,000</td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: middle">
<td style="padding-bottom: 1pt">Available for sale securities</td>
<td style="border-bottom: black 1pt solid; text-align: right">                                       281,800</td>
<td style="border-bottom: black 1pt solid; text-align: right">                       281,800</td>
<td style="border-bottom: black 1pt solid; text-align: right; padding-bottom: 1pt">                           -   </td>
<td style="border-bottom: black 1pt solid; text-align: right">                               -   </td></tr>
<tr style="vertical-align: middle">
<td>Total</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                 1,063,800</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                 1,063,800</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                            -   </td></tr>
<tr style="vertical-align: middle">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td>Liabilities:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: middle">
<td> Contingent consideration</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                                    367,100</td>
<td style="border-bottom: black 2pt double; text-align: right"> $                              -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                        -   </td>
<td style="border-bottom: black 2pt double; text-align: right"> $                   367,100</td></tr>
</table>
<p style="margin: 0pt"></p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 42%"> </td>
<td style="border-bottom: Black 0.5pt solid; width: 25%; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; width: 18%; text-align: right">Fair Value</td>
<td style="border-bottom: Black 0.5pt solid; width: 15%; text-align: right">Unrealized Holding Gain (Loss)</td></tr>
<tr style="vertical-align: bottom">
<td>At September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Available for sale:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Equity securities</td>
<td style="text-align: right"> $                                      29,300</td>
<td style="text-align: right"> $                      34,000</td>
<td style="text-align: right"> $                  4,700</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">  Mutual funds</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                                       254,800</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                       243,000</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                  (11,800)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                                    284,100</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                    277,000</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                 (7,100)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Fair Value</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Unrealized Holding Gain (Loss)</td></tr>
<tr style="vertical-align: bottom">
<td>At June 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Available for sale:</td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>  Equity securities</td>
<td style="text-align: right"> $                                      29,300</td>
<td style="text-align: right"> $                      35,800</td>
<td style="text-align: right"> $                  6,500</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">  Mutual funds</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                                       255,800</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                       246,000</td>
<td style="border-bottom: Black 1pt solid; text-align: right">                    (9,800)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                                    285,100</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                    281,800</td>
<td style="border-bottom: Black 2pt double; text-align: right; border-top-color: Black; border-top-width: 0.5pt"> $                 (3,300)</td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 38%"> </td>
<td style="width: 31%"> </td>
<td style="width: 31%"> </td></tr>
<tr>
<td style="vertical-align: bottom"> </td>
<td style="vertical-align: middle; border-bottom: Black 0.5pt solid; text-align: right">September 30, 2015</td>
<td style="vertical-align: middle; border-bottom: Black 0.5pt solid; text-align: right">June 30, 2015</td></tr>
<tr style="vertical-align: bottom">
<td>Raw materials</td>
<td style="text-align: right"> $                     1,358,600</td>
<td style="text-align: right"> $                    1,420,800</td></tr>
<tr style="vertical-align: bottom">
<td>Work in process</td>
<td style="text-align: right">                           652,300</td>
<td style="text-align: right">                          442,900</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Finished goods</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                           332,900</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                          350,000</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $                     2,343,800</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right"> $                    2,213,700</td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 66%">Loss per common share was computed as follows:</td>
<td style="width: 17%"> </td>
<td style="width: 17%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td>For the Three Month</td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td>Periods Ended</td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid">September 30, </td>
<td style="border-bottom: Black 0.5pt solid"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">2015</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">2014</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Net loss</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                  (60,100)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                (161,300)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1pt">Weighted average common shares outstanding</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                 1,489,112</td>
<td style="text-align: right; border-bottom: Black 1pt solid">                 1,469,112</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Weighted average dilutive common shares outstanding</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">                 1,489,112</td>
<td style="border-top: Black 0.5pt solid; border-bottom: Black 2pt double; text-align: right">                 1,469,112</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Basic loss per common share</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.04)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.11)</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="text-align: right"> </td>
<td style="text-align: right"> </td></tr>
<tr style="vertical-align: bottom">
<td>Diluted loss per common share</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.04)</td>
<td style="border-bottom: Black 2pt double; text-align: right"> $                      (0.11)</td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="width: 55%">The components of other intangible assets are as follows:</td>
<td style="width: 9%"> </td>
<td style="width: 12%"> </td>
<td style="width: 12%"> </td>
<td style="width: 12%"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid; text-align: center">Useful Lives</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Accumulated Amortization</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Net</td></tr>
<tr style="vertical-align: bottom">
<td>At September 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Technology, trademarks</td>
<td>5/10 yrs.</td>
<td style="text-align: right"> $                 1,215,800</td>
<td style="text-align: right"> $                    649,400</td>
<td style="text-align: right"> $                    566,400</td></tr>
<tr style="vertical-align: bottom">
<td>Trade names</td>
<td>6 yrs.</td>
<td style="text-align: right">                       140,000</td>
<td style="text-align: right">                         36,900</td>
<td style="text-align: right">103,100</td></tr>
<tr style="vertical-align: bottom">
<td>Websites</td>
<td>5 yrs.</td>
<td style="text-align: right">                       210,000</td>
<td style="text-align: right">                         66,500</td>
<td style="text-align: right">143,500</td></tr>
<tr style="vertical-align: bottom">
<td>Customer relationships</td>
<td>9/10 yrs.</td>
<td style="text-align: right">                       357,000</td>
<td style="text-align: right">                       240,900</td>
<td style="text-align: right">116,100</td></tr>
<tr style="vertical-align: bottom">
<td>Sublicense agreements</td>
<td>10 yrs.</td>
<td style="text-align: right">                       294,000</td>
<td style="text-align: right">                       113,900</td>
<td style="text-align: right">180,100</td></tr>
<tr style="vertical-align: bottom">
<td>Non-compete agreements</td>
<td>5 yrs.</td>
<td style="text-align: right">                       384,000</td>
<td style="text-align: right">                       196,800</td>
<td style="text-align: right">187,200</td></tr>
<tr style="vertical-align: bottom">
<td>Intellectual Property, Research and Development (IPR&D)</td>
<td>3 yrs.</td>
<td style="text-align: right">                       110,000</td>
<td style="text-align: right">                         58,100</td>
<td style="text-align: right">51,900</td></tr>
<tr style="vertical-align: bottom">
<td>Other intangible assets</td>
<td>5 yrs.</td>
<td style="text-align: right">                       164,100</td>
<td style="text-align: right">                       149,400</td>
<td style="text-align: right">14,700</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 2,874,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,511,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,363,000</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td style="border-bottom: Black 0.5pt solid">Useful Lives</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Cost</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Accumulated Amortization</td>
<td style="border-bottom: Black 0.5pt solid; text-align: right">Net</td></tr>
<tr style="vertical-align: bottom">
<td>At June 30, 2015:</td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td> </td>
<td> </td>
<td> </td></tr>
<tr style="vertical-align: bottom">
<td>Technology,  trademarks</td>
<td>5/10 yrs.</td>
<td style="text-align: right"> $                 1,226,800</td>
<td style="text-align: right"> $                    624,200</td>
<td style="text-align: right"> $                    602,600</td></tr>
<tr style="vertical-align: bottom">
<td>Trade names</td>
<td>6 yrs.</td>
<td style="text-align: right">                       140,000</td>
<td style="text-align: right">                         31,100</td>
<td style="text-align: right">                       108,900</td></tr>
<tr style="vertical-align: bottom">
<td>Websites</td>
<td>5 yrs.</td>
<td style="text-align: right">                       210,000</td>
<td style="text-align: right">                         56,000</td>
<td style="text-align: right">                       154,000</td></tr>
<tr style="vertical-align: bottom">
<td>Customer relationships</td>
<td>10 yrs.</td>
<td style="text-align: right">                       357,000</td>
<td style="text-align: right">                       236,200</td>
<td style="text-align: right">                       120,800</td></tr>
<tr style="vertical-align: bottom">
<td>Sublicense agreements</td>
<td>10 yrs.</td>
<td style="text-align: right">                       294,000</td>
<td style="text-align: right">                       106,600</td>
<td style="text-align: right">                       187,400</td></tr>
<tr style="vertical-align: bottom">
<td>Non-compete agreements</td>
<td>5 yrs.</td>
<td style="text-align: right">                       384,000</td>
<td style="text-align: right">                       182,700</td>
<td style="text-align: right">                       201,300</td></tr>
<tr style="vertical-align: bottom">
<td>Intellectual Property, Research and Development (IPR&D)</td>
<td>3 yrs.</td>
<td style="text-align: right">                       110,000</td>
<td style="text-align: right">                         48,900</td>
<td style="text-align: right">                         61,100</td></tr>
<tr style="vertical-align: bottom">
<td>Other intangible assets</td>
<td>5 yrs.</td>
<td style="text-align: right">                       164,000</td>
<td style="text-align: right">                       148,200</td>
<td style="text-align: right">                         15,800</td></tr>
<tr style="vertical-align: bottom">
<td> </td>
<td> </td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 2,885,800</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,433,900</td>
<td style="border-top: Black 1pt solid; border-bottom: Black 2pt double; text-align: right"> $                 1,451,900</td></tr>
</table>
1587500
1210000
115400
118100
144000
6500
18300
0
900
0
1600
0
0
6500
20800
4056400
4074800
1613200
1507400
730700
786600
564400
574900
6964700
6943700
54700
-118100
-82000
-70200
-30100
-40400
-8100
0
-65500
-228700
599000
411100
7800
443500
0
0
0
0
606800
854600
1263000
1086400
153000
551100
28500
24600
0
0
1444500
1662100
1107200
1063800
1107200
1063800
0
0
0
0
266200
367100
0
0
0
0
266200
367100
-7100
-3300
-11800
-9800
4700
6500
277000
281800
243000
246000
34000
35800
284100
285100
254800
255800
29300
29300
332900
350000
652300
442900
1358600
1420800
1489112
1469112
1489112
1469112
38500
51000
1511900
1433900
649400
624200
240900
236200
113900
106600
196800
182700
149400
148200
36900
66500
58100
31100
56000
48900
2874900
2885800
1215800
1226800
357000
357000
294000
294000
384000
384000
164100
164000
140000
210000
110000
140000
210000
110000
P5Y
P5Y
P9Y
P10Y
P10Y
P10Y
P6Y
P6Y
P5Y
P5Y
P10Y
P10Y
P10Y
P5Y
P5Y
P3Y
P3Y
P5Y
P5Y
248100
337000
324000
246600
80400
126900
86300
88100
-2700
0
0
25400
.47
.46
.13
.13
.76
.99
.21
.19
EX-101.SCH
5
scnd-20150930.xsd
XBRL FILE
00000001 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
link:presentationLink
link:calculationLink
link:definitionLink
00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
link:presentationLink
link:calculationLink
link:definitionLink
00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
link:presentationLink
link:calculationLink
link:definitionLink
00000007 - Disclosure - 1. Summary of significant accounting policies
link:presentationLink
link:calculationLink
link:definitionLink
00000008 - Disclosure - 2. New Accounting Pronouncements
link:presentationLink
link:calculationLink
link:definitionLink
00000009 - Disclosure - 3. Acquisition
link:presentationLink
link:calculationLink
link:definitionLink
00000010 - Disclosure - 4. Segment Information and Concentrations
link:presentationLink
link:calculationLink
link:definitionLink
00000011 - Disclosure - 5. Fair Value of Financial Instruments
link:presentationLink
link:calculationLink
link:definitionLink
00000012 - Disclosure - 6. Inventories
link:presentationLink
link:calculationLink
link:definitionLink
00000013 - Disclosure - 7. Earnings (Loss) per common share
link:presentationLink
link:calculationLink
link:definitionLink
00000014 - Disclosure - 8. Goodwill and Other Intangible Assets
link:presentationLink
link:calculationLink
link:definitionLink
00000015 - Disclosure - 1. Summary of significant accounting policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
00000016 - Disclosure - 3. Acquisition (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000017 - Disclosure - 4. Segment Information and Concentrations (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000018 - Disclosure - 5. Fair Value of Financial Instruments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000019 - Disclosure - 6. Inventories (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000020 - Disclosure - 7. Earnings (Loss) per common share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000021 - Disclosure - 8. Goodwill and Other Intangible Assets (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
00000022 - Disclosure - 3. Acquisition (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000023 - Disclosure - 3. Acquisition (Details 1)
link:presentationLink
link:calculationLink
link:definitionLink
00000024 - Disclosure - 4. Segment Information and Concentrations (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000025 - Disclosure - 4. Segment Information and Concentrations (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
00000026 - Disclosure - 5. Fair Value of Financial Instruments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000027 - Disclosure - 5. Fair Value of Financial Instruments (Details 1)
link:presentationLink
link:calculationLink
link:definitionLink
00000028 - Disclosure - 6. Inventories (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000029 - Disclosure - 7. Earnings (Loss) per common share (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000030 - Disclosure - 7. Earnings (Loss) per common share (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
00000031 - Disclosure - 8. Goodwill and Other Intangible Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
00000032 - Disclosure - 8. Goodwill and Other Intangible Assets (Details Narrative)
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.CAL
6
scnd-20150930_cal.xml
XBRL FILE
EX-101.DEF
7
scnd-20150930_def.xml
XBRL FILE
EX-101.LAB
8
scnd-20150930_lab.xml
XBRL FILE
Benchtop Laboratory Equipment [Member]
Business Segments [Axis]
Catalyst Research Instruments [Member]
Bioprocessing Systems [Member]
Corporate and Other [Member]
Consolidated [Member]
Level 1
Fair Value, Hierarchy [Axis]
Level 2
Level 3
Available for Sale
Major Types of Debt and Equity Securities [Axis]
Mutual Funds
Equity Securities
Technology, trademarks
Finite-Lived Intangible Assets by Major Class [Axis]
Customer relationships
Sublicense agreements
Non-compete agreements
Other intangible assets
TwoCustomers [Member]
MajorCustomers [Axis]
Five Customers [Member]
Three Different Customers [Member]
CustomerTwoMember
One Customer [Member]
Trade names [Member]
Websites [Member]
IPR and D [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Is Entity a Well-known Seasoned Issuer?
Is Entity a Voluntary Filer?
Is Entity's Reporting Status Current?
Entity Filer Category
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current Assets:
Cash and cash equivalents
Restricted cash
Investment securities
Trade accounts receivable, net
Inventories
Prepaid expenses and other current assets
Deferred taxes
Total current assets
Property and equipment at cost, net
Intangible assets, net
Goodwill
Other assets
Deferred taxes
Total assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable
Customer advances
Bank line of credit
Notes payable, current portion
Accrued expenses and taxes
Contingent consideration payable, current portion
Total current liabilities
Contingent consideration payable, less current portion
Total liabilities
Shareholders' equity:
Common stock, $.05 par value; authorized 7,000,000 shares; 1,508,914 outstanding at September 30, 2015 and June 30, 2015
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Total
Less common stock held in treasury, at cost, 19,802 shares
Total shareholders' equity
Total liabilities and shareholders' equity
Common stock,par value
Common stock, authorized shares
Common stock, issued shares
Common stock, outstanding shares
Stock held in treasury, shares
Income Statement [Abstract]
Revenues
Cost of sales
Gross profit
Operating expenses:
General & administrative
Selling
Research & development
Total operating expenses
Loss from operations
Other income (expense):
Investment income
Other income (expense)
Interest expense
Total other income, (expense) net
Loss before income tax benefit
Income tax expense (benefit): Current
Income tax expense (benefit): Deferred
Total income tax benefit
Net loss
Basic earnings (loss) per common share
Diluted earnings (loss) per common share
Cash dividends declared per common share
Condensed Consolidated Statements Of Comprehensive Income Loss
Net loss
Other comprehensive loss:
Unrealized holding loss arising during period, net of tax
Comprehensive loss
Statement of Cash Flows [Abstract]
Operating activities:
Adjustments to reconcile net income to net cash used in operating activities:
Loss on sale of investments
Loss on asset disposal
Depreciation and amortization
Deferred income taxes
Stock-based compensation
Income tax benefit of stock options exercised
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable
Customer advances
Accrued expenses and taxes
Other assets
Total adjustments
Net cash used in operating activities
Investing activities:
Cash paid for asset acquisition
Redemption of investment securities, available-for-sale
Purchase of investment securities, available for sale
Capital expenditures
Purchase of other intangible assets
Net cash provided by (used in) investing activities
Financing activities:
Line of credit proceeds
Line of credit repayments
Payments of contingent consideration
Proceeds from exercise of stock options
Cash dividend declared and paid
Principal payments on note payable
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of period
Supplemental disclosures:
Cash paid during the period for:
Income Taxes
Interest
Notes to Financial Statements
Summary of significant accounting policies
New Accounting Pronouncements
Text Block [Abstract]
Acquisition
Segment Reporting [Abstract]
Segment Information and Concentrations
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments
Inventory Disclosure [Abstract]
Inventories
Equity [Abstract]
Earnings (Loss) per common share
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets
Principles of consolidation
New Accounting Pronouncements
Purchase Price Allocation
Pro Forma Results
Segment Information
Fair Value Inputs
Investments in Marketable Securitites
Inventories
Earnings per common share
Intangible Assets
Acquisition Details
Current assets
Property and equipment
Goodwill
Other intangible assets
Total Purchase Price
Net Sales
Net Income loss
Net loss per share - basic
Net loss per share - diluted
Statement [Table]
Statement [Line Items]
Segments [Axis]
Revenues
Foreign Sales
Income(Loss) from Operations
Assets
Long-lived Asset Expenditures
Depreciation and Amortization
Customer [Axis]
NumberOfCustomerAxis [Axis]
Net sales
Consolidated sales
Assets
Available for sale securities
Total
Liabilities:
Contingent consideration
Cost
Fair Value
Unrealized Holding Gain (Loss)
Inventories Details
Raw Materials
Work in process
Finished Goods
Inventory
Earnings Loss Per Common Share Details
Net income (loss)
Weighted average common shares outstanding
Effect of dilutive securities
Weighted average dilutive common shares outstanding
Basic earnings/(loss) per common share
Diluted earnings/(loss) per common share
Common stock issuable upon the exercise of outstanding stock options
Useful Lives
Useful Lives Minimum
Useful Lives Maximum
Cost
Accumulated Amortization
Net
Goodwill And Other Intangible Assets Details Narrative
Estimated future amortization expense 2016
Estimated future amortization expense 2017
Estimated future amortization expense 2018
Estimated future amortization expense 2019
Estimated future amortization expense 2020
Estimated future amortization expense thereafter
Total amortization expense
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Custom Element.
Assets, Current
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent
Assets [Default Label]
Liabilities, Current
Liabilities
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Gross Profit
Operating Expenses
Operating Income (Loss)
Interest Expense
Other Income
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest
Income Tax Expense (Benefit)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Gain (Loss) on Sale of Investments
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Customer Advances
Increase (Decrease) in Accrued Liabilities
Increase (Decrease) in Other Operating Assets
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Businesses, Gross
Payments to Acquire Available-for-sale Securities
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Intangible Assets
Net Cash Provided by (Used in) Investing Activities
Repayments of Notes Payable
Inventory Disclosure [Text Block]
New Accounting Pronouncements, Policy [Policy Text Block]
Schedule of Inventory, Current [Table Text Block]
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill
Revenue, Net
Assets, Fair Value Disclosure
Finite-Lived Intangible Assets, Gross
EX-101.PRE
9
scnd-20150930_pre.xml
XBRL FILE
ZIP
10
0000087802-15-000009-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0000087802-15-000009-xbrl.zip
M4$L#!!0````(`)9Q;$>"#4;JE4T``*N*!``1`!P`S'Q*P20D84(1&I*RK?SZO0!)B:`HOBU1;:6K
MNA42P#FXN/?BXLG/?WV;&NB%6#9EYIC;\-:?W@Y&!RA
MO_[TW_^%X+_/_U.KH1M*#/T,73&M-C!'[!S=X2DY0S\3DUC88=8Y^@>:0Y](?#4A3E#S9,N1K5:BC*';&YI9%F@VNHT.BI2>@VEKJ@MI"J_
MJB=O(T"\P@Z\YP__MWZEJORO^I/:/E,;9_5N2BP'.W-[B:6\=15`492&F_WS
MV[-ET#/^-P*AF?;9FTV_'$T<9W9V>OKZ^GKRVCAAUO@4\JBG__QZ.]0F9(IK
MU+0=;&KDR,]E4/./J'QJK]<[%6_]I&LI.;B/T3CEKY^QO2J9$XQ)O\8$WNK.
M,D,P<>O4?2DEI9%)VVY2ZB?522B=3;23,7LYA1>07FW6%+764/WD%AEMI-P^
MA;=^0FJS9EWMQ-7/3>%GF-NU,<:S9881MI]%8N\%)].2R<`;BQG$CLPCWD1D
M,IEISJ?1O'3'.G46,W(*B6J0BEA46^9+SB1G``[\<30[\2:"W?#R[FJ9P=8H
M,1TZHAHU];GM6)38)QJ;BGS#7XY^4OA_W4Y7J7\^#6=>P9U&XGEH,V@&
MIJ^S`'NR'.YZ?EI5QR]I]6XM&S'U0"9>[Q6\+F7QGTL$_(>>2#?+N6_?C_96
MMJZW&'BL-DM?F:B^U]<_V=.9U.HR%0T@V&O&[BC,<%A.>_F-O4)+8]
M=(NS^V_4/OJ).]BS1"%\/HW$"W(]C2;[77HF3Y^:`7UJ'O1I7_2IF4>?FEO0
MIRC_=(D=;"QLYY'8!%O:9`".T9H+@7\)@U+L@5*\WVI7"@]1/RA#2!0'#W%0BHHIQ4X]1..@#"%1
M'#S$02DJIA1;\Q!?Y\X<&S=S4_].1J5?\;^9]<0W'=Z/KLBSTS=UOD7!60R)
M-K?$Z#,P2;]6_0_B"[2Y[;#IH?4KU?I;,_JP2#Y8V_L9HL7P03R`'PT<=*&R
MNK`U?_!D89U,L?7'=]+Z-]2D#KFE+T0?F""V,7TV2-^VB6-?+(1J7!K8#FE`
M6`@?S`\<=*!R.K`U^[\4T2"Q'HF!'9"B/:&SCZP&,?+X8%[AH!E[HAE;\Q6W
M5..2-,?]L47(=[2].)<^;)3&!_,3!ZW8`ZW87CP!K_CI^CDV'NEX\J%U88,L
M/IA_.&A$Q35B:[Y![$0-"^L#:T.,/#Z8CSAHQIYHQKL?YX_81[MG]Q_LQU;3
MYK[?+='<6X[?O3>(WIZ?:W_VM"1M5>TT6V]?L:M_64#VO'1I*2TNW_*[([T1E
M\R_=!H3P_0^>>X&-?+^19QMD]A$50'@2N?X?J^T'#X\8W,Q';7JI^M]KR\?$
M-(<-/!7:P%/Q`")BV'?8!U9U->Z["MNY+;NO??
M:QT4J_J*M9<>Z[#1O'(;S???6QV4JMI*M5>>ZK!JN_-5V_WU2`?EJ9;R[)7G
M.1RTJ?Q!F_WU3`?EVB_EJI[G6AU*VL,#7_*AI-W5?:Z>_0J\#Y"BCG7Z)G*#>C5ZCB4J:\?"?,2?MR3
M88DB2C:Q+#SV_Z18-R.$)P21*#<&\'O8@*/3%S"*==GRO'>@$^*,[+HN9I!!F&-4
MJ0'0*V*R*3638)/E$L:-*MA_+TDAA4`?B*6!BB>TV@Q^IF\SG="S:V$VCV1,
MP2+!D?/X&WGZ^4A&<1-2W+8'UW=/@YO!)1K<77T;/CT.KH?P\_+SZ::RU[$O
M"5^1,`:F3MY^(8O4X$%?N[&T(-P5TX3+X?=*IT:!SNY7M_Q@]JAB'X2E7[M^
M('7YP2F?C:4%X?KP5NP="RK`AM+68?_!C#G$I];B
MAAK04>:$"Y42H=ZN'![)C%D._Y0T=)?S]&C_XLXFJ;1U5,$&>ETR9E9ZDQI.
ML0'YT+)X=,FF,VPN@A2DHJ,,P6UR5X%OX%GZROZJRD:P5M)F.*YAV<#@=SL*
M;EF2#[9:.IU.F3ETF/;'`[;N+1'XZ.+[,T!1]'82N'S<\PAQURM>!#I'I!.-
M@M3M+T>#NQMP:B=*Z_-I!L3R2+9W0M*%Z,^=";/HGT1/)\$-Q#JB3U`BN86!
MBG-JOQNG@+V'$]_/'3[@TKEQ1M)RAY>)M-1FMZ>J5S12]2Z/;
M50LS[+]@:N!G@]PP:P@Y5E\>\B+TO'U?O=.1O%HB4%G,$ENVWE6[.V%6J*_;
MJ3P+]W'5DWG&KJ$ZXJXJ\;+ZLNI(^MV):QJ;@XM^)!H!=PTY[XA3T.UV&IVF
M9&@Q&"7P272VJM)5.WD)#,JL!23)W0\UF@W)]00+S0&8W+W453ERB`-\
ML,@,4_WZ;49,F_`U+KY-RUUD+J@):A.&1P$:*:#*8Y*$_
MX32X!.*"WI9)17\>.G9MH-UN[D!RF^^OC(V&E7I[%Q*-
MN[0E/C1MJ[L4;F[>=:6["SEOOF8BEFU7V:F4\[+N;-OP8C_VF,"UOE,]SL$9
MBFGL0KYQ!^KBNXO.+D6LA3OPYNH0YUIV0S='\K>8NPMGLS=]6"QC4SXSIK]0P
M1IS$0#XM3F`N]HZ96K%9Q59=<@"191
MW+6:K?R_CAQ$!,K,#I>L2(V>JJ2$"QSZ
M*'1FH].2@X-0L3EADV.2;+!]'7IK:&-L/&`*8])+/*,.-@+98KG=:2C,;>"`X@*%;>7)8FY9*`BJ)6/:IK*S$)&URC\H6.K:L]L0E%C'%YV>0
M[I!R=@9KAX7%-0O%CF^K+:7;4YLQ1Z5=D&)<4DJD+"Z)![9+$T[<<>WLK,H2
M4PPK?MK#?B0OQ)P3OHBRMAP5$$"C];$"4_6&Q$2]&*5J\EM4.@
M^(S(62L.NEA/BTQ,8F$#NJ&^/J6FN#C)@6&#=\*C##DTE:[,)AZR!(99Y=6H
MMUL%&`Z)88"W*5%D:EL^1"HC9,?/*I!Z3UYQCL?W+]D#>5WQ+=(E%J\PN1I&C[TSL[F=B=G`IVM2W"<4&PFU%FOQ;`\G%(JM<.G5YMTMZ
M%JLIBS*D46NW6I$\5C`YF6252*U>[W8R4N&'$FV':Y";9@`L(,@II8.2C&H3
M4!%"606T=OXS#2$QY77'3"8+LQ35D<>3&Y`*$,HJH'8]!Q]?<&4Z9%5N*0D@
M!WYFGUO/@._M+"U-*51YJB=0?$;DS&%=-R7NRIUP)'<]:@[ZX?D;9MKNM)R;
M[@F_$?OZ#6(<9L&H"5N+@4.F8I<5W_;,1-=?IM^I=3H]N?W>C>Z.)9.CAZCO
M2C3>HN2R),^:+B`6+FE`).WEB0,K3BVSX%OR`8-L_/S-=^\HNYK:D:P_`;($
MAIE%V(S<))F2X!9%5SZCS*)JJ^T6@MJ63\C$PONK
M8.R3>GET]6'F(!
M8N\DKPW$-JV:?S,M@@U^4>K?F,$GE'_&U.3*>6^N+@WJ6Y2?O;N"_S7'[M7!
MD>O[>6VTL1[UO0/578HDL^-8'Y5M02(1$*6V<[L1FJO>"%>060X_';KX-#VU
M@,RQ0>Y'JT%]*1U8<,YV,U)!4MGE)9_624_LBH!<-2H">_AM$/Z#ST)/^4[!
M/_':%L6\T\M**W1C43+N.W+]'>(=;>*PV2U^9N*[&8OE%0XISH!U&MU=52;J
MNT$%*]-6JM0RR1\UBM^14:6&*5:7WLZ4+-)B*)M93",V[[V&4"D8YJ1`*$6AI,9$T(1,-DY],]C7E[&RNIS.#
M+0@9$NN%:B0Z$X3HWN32HS.`UP660S[^_IMLJGZE\7'#XW
ME7=,UE#4>)(!P,+LLB],M1-:.Q,[^1KA,L37:7?B^\<$R\[.CFZ
M&;H^*PUP660SJVCHY%L>KGW]WW-OIO")0=?$3(V*:_A7JV1/C-\'^V`Q_G%7
M_6+QS>8KKLM]97W-H2^E-8#:"IWI+(_>MJN>N3E[W>:VZLZOB]]>H]::\KI]
M>O1R>6>/2%J]3C'BXK3^(]')5,32P:GYP`I1Z&LA)8V*_?2U_\RI139>XUS*\%X*&-)CE\LZ\SR`K.(ET@Y?CU?R8#\1KQ2"
M.6:@BG#R4-KC#
M&VK"T+KT+J37"V_O3`E>+NVLLNW)U]GEIQW]R11WFU=X0%[*@:INBL]<1\.7
M33W[IB6EU2Z+?.`T`K_NJ92YA[4I_"!"#@*99\FRX;MG+,JJ?3-T5&]5>E;D
MNP^.T1`4YV(90OM`6T'+H8&I
MS_GGIC@T:/@)^N35IMDY7R7SGW7/CQ%&5\3`K]CB3LC=1P+"_?$8]0T'3ZF%
M46"7E5MHH$P_4:!$01&CUPDSC`5BKR94R9X_0^1&L;5`V-0W(0;J\8"U/_"8
MBV:]1M@$:6#>99!-*"X'0.(-\B]F_2$A"0X!,&D3DXMR+`GN8B!++'/=3@2A
MOF$@]XUA$,$?"K&\4S;(80C;B+?M"OG259$5^@GBA4Q!+2RN()1;LZ='Z!D;
M[HH"I^%8V+2YD/@J^`2#J)X),1$QZ!2$!VIVLE+NP#Z%5!Y`&AJ`A`-)+6;"
M3\U5VJV[#/C3AN3*S#E''*^&#:C0&3+(R']"39WP8B&-,,6!B;[B!>*^]%@(
M_Z8_O$#4O0VH/_R&/"][C+S[5]`(^(OFY`,3_DD9&[U29X+\11:0/]1>7)-C
M>5DLHC$0K!@H643,5+A6/6(6FLX-AWNXF@Z-\P*C&Q[?^CFQ!>TX=E.?H*<)
MM=%\QMT$FKG!E"VHC.?@.T#L"``F['69'9)[V'^Z&J:3&=4<45&A(:![W(-`
M85,Q!!GSFU40L++=[0TVSZ0M:T9-4"ZH'V]N*`0[7'VY+MM+QZ1)PT+(_3JA
MVD0@V@`-)1-WK0)KZZ0"\^Q1L>3@4Y`[X4B
M;X121MPQV`Z9V6?H$_T145T8^@)Y]$2CN6TFGGBUXXG#J6?$`BI35[3/H$SN
MB4W.-5C8.<\*>7U:*S<=,$,0,M2`)WT!#V2`7?!FC$S$19,)GEO\)RAVV=B^
M!@@BKQ.P_$\@16S_&&P(OE?%'O&0'V^`.@%GB/X^-X2!M`(&HB^]%B]N-'+=
M&1*:">1'U-;`/2T(MES->"9@H?P@#\(CD!%X24ULC4.\5"B[>XR\)O=I0Y_\VK#6Z"'=29&MER9>2GB_BALZ5PW9KQ-''!Y;M?T
M/'>0R1S0/7[L5J1F%@5Z@!6J"106)MKA&KADR8LG$%C/Q?I$0!CP$UXMS5)\
M.T1X869*EA+?Z?/Z643<7XETD(;![#D$;R?O$)>X?Z(P3_*1:/T;2
M3CJOYVHI+DGWKDHIQ:T-,%W/A-%#0*>?H*+$\?SVW-"YZ^EK$PIF`OR%3O(R'[EW
MYM_80=[^+N2.EV3?BT4;<]\ZXQL=@2WQ-GRZT&,P:.%D*6BNMU_,[\/;YYZO
M%(2\#'Z!WI0JJ(9'$?L4\9*BM:3H.46NX!Y%@DQHZ:7R>WV-#Q(T\@"':`HB
MB.`O,G&Q/3(\O0,C2ZZY..Q?0/'=NX3=L&B-MK"6YZ!?&;[KD.:-*YCO0=9N0[!X8Z=B!0U%1K3I=MH
MGOM;TA9G:`C"-Z!?]OWL5W'?I'"47-C+E,N\QWZ`XMD`]5.(IIVZV74TMX7]
M4KYO?JD*!K8=R'`,;6S!+P9=QJ?;PX_Z$PZ,9)7S@9O2U/[PZ03KIG<]"/W*1G!_MIHO9V*1K'\F5VR#GY]ZLL$SY;!QDS-/";^$GTL^!G`%K+T,@*_"!;)VC1OA!ASR^P+[/Y<[)#I[385.[
M+37E`W\86L
M)Z^PU4YAY:V58SJ!?T]][T
M):DG21(J&-S`>D0&=FC:@(3L\C[#`C#G)5P)-^^8RF*Z[XVF]'LZO(Z(LZ$9
M/2;6G[C;IOT$^-:8GK[`;-'<0SKAXK3A-^N9T0IU)M(M3(W\5+=Q;J3"`/H>
MO@G#F&\SNR$Q2I:]"%D#W+R8Y^CWR"!_987;@7I*EDH?8V@4'S78O&5Y\T?[
MO8)NYZ8:4!?9Q/4_3/B-9G!6^%S7IPY*@?]<*#)#>4X"'7ZNPP]2%YQTQ(Z"
M=9>2"6-40]QU@*-T&G$%/?+!97U-=]^"YKTB-RL^S-#)^(HN>A(ZX$B]D4&X
M!HETO!F8#!ZR>_S<+1Z#P!"0JV@<(M'@K1R=E!OL9>Z5`,5R5=^6G:,H5WH-
MA;9@@*6:J$5K;&L4V?Z7J*FPEP0.,'2#XA`Z$\<%V4VTV4)<$GP:XJ,!1=*K
MTR2_.TVRE*9450*RJ&TM+%,9XV)/U%!H3?)P#"K6@+LIV-N=HM#$(`1\(7WW
M`]"*R?A][3UY`N,DV<,SW5T(7.$<$GW*(LF9;@WML>^[\$OL8?`M9%Y0'KJL7-^%
M;9PR)=,"=^VG=4J`F^8@?"#T>))';-B5I[AO>L_9OY.ES/Z=(/3J#*/Q+[!+
M26_?)Z]?XI&#-0WI+R2%WI.*B/^48X9(!>DPL$`B!X0\=?B>_`@66_XTVJGL
MC>$"8H;ZMDQTHN'F5Q5IW:L,#'9&MRIN>T'D)F;]X7@ZXV8Z%3WP`/O<+Y#K
M30'AHX%D34/+IR4*IQFX/<)R<-/@@_D^W[AVI_NI0+)L]N366)&VQ1;TSNFM
M][16Z)V^D6PHE_Q)V#92%YS9I];,/;-F-M(_(388X2FE);36.*U7\$*!OP_]&-@\'\0]HBU$
M[NDF"S9L8,;/S*Q:L+;V9]3M/@(8W^H>C>]++0_MI\D3NG:E)"C\WT?PT3%?
MEIB]0N)*JLG1XV/(K%(G>69+VQ1;/8?V/9=OW,]XDVF,S/-(HU;YV]A@`_^`&LSB>M0>^SYKO_,(X:O]`G]OB0AQ4+G>A2[Q'5&+%2DIY'R
M-[)2_KW48>:Q(PP?CYTI]RWY)[U"G&KAZX/\Z]H*;'FNPY`2#SW]C5\T\B\F
M>I8A4O+5N_N'S&R[W?QAM7AD\$9905S/]]"?GM*H$#?EM$W"`*M'2$C=HE`7
M$IALW_.HG1Q=)EDMA;!@;\Y5IBP!=)@>KO@@)BS0=LECD^RTFKG8A5!Q^M%I
M0%\(?<
M.B\\F,(2ZUB0Q&>#?&$1H31-H/`Q'G#)49]8,W8B]2/B`<2G&9G$4&39$`>_+,8_5N,W:7AN3*$T^-3^,I3#'_BJ"Y%^XIIIFMCI_E&^:ZWF:AC)!-KL"@E`!ILB"3)LUC
MG:4>VIP/E\Y:?;O*75NO2_:"POJUW2`*VFHJE"[!_->?:S*`4^4$^Y$LD]Q5`7XZTG-<,-\]?/
M>?;;0XJY&`\6Y&H`NMSPX*G26^YIFE;AA*&N_O[D!Q0>(ZS;NS@"32%],&A&
MZYT;U.^9@FQ=@EI7G`(2+&@(,B1C47TTN-4E'94OL,KJ.W:CGN3]<`43UD&Z
MUNL+M9Y#%Z:"YL$[09&*]%(ES.`3]-H@58)(\P0Q='1]WK6T(325WWP\D-:3
M=&,QM_/4)RWW#%GM*>\^5G
MAQ5"8;>%6?N:H8.I)6>EDIMB5R-!9P%M@H0O?S208-7!(<&"MO5\@UMRL;$J
M2R`J=E053*L&]55Q`%)/L`>";+M`RM(IL:!@.Y#8U"I"LJ0OAEU*MJL6[T8>
M9UKZKH7>DRL^Q/%8\%Z2-?EQ:),9S3[[2'PSPU!KN-SQCM*
M;[EG&$J+5='$O8!22),;TGJG`FF:*N*.W8)$?/+@D&!!1!^J;13.CJ5"`=%LV992L9O0$X^N(Z0`Z&OUN5!>/1I&SKUK7W[Q`-/*#\<6.[#W61!Z1'KQ=W3T)
MF,X3?:]XJAAK!+.V\`M>?&EE*N,W&0:%[,*)^UI&%]O5_'/ADZ
MHQ%VE<E(*]7OYE$=)GB-?-JQC>]K)?;'_#JS%
MCS'V[>6>>^A8>Z%0V1`K_[,_BR9O3%:AI=AB%[)/EA/\TW)C6M:R;-_]QS+Q
M^'3]^`$VRA%VCV-+9`1HLL;MK+T>_&Z!9,`**:@SKKOXX]8$ESB`H*E>_=C%
M]F*PFFS*=EZ0I9"RYI2\S2(H'C*U'-Y.,+"\$%43*C'KR7&="'M"X;-,/:$H
MXB,6[SOU1*-72KVD,16WGRR,0X'8HHJU(MZW"K0E4)9I"+R"=44^Y1,J_!$4
M&S8>3/N=T;FQ;#^,6E$%!UC_B1)&'?X<.T/LYD8L-_3!H`3"#3D7AYE(`N]8
M2\$"HP-X?UB4"U0%-$3_R@G'J$&*?QP[H)9!5<]0?/"GY#*N-XV!IJQK8/X(
MZ!VP8R/GKT3X^%.$M4ODNXT+BMGEB#Q9(66MSO!)UF@P0CEZ'3MLMV5OQB$W
M(#BG6=_"`MXP/?\II,$+N^R:V!E!B[83HCQ[;XI!96XAPNW'G`KH#P
M3V!5Q)LQABD*;)Y#&MJ!\X1C4QBV_-;S40CS0"LS?OFO!10&[S\SLLKI/^^X
M1#`"(T68^#"LXJF//0FM(6IYH-!_8A__;XIMG[E)R-IGLD9[12N.M51EXF4Q
M6R81G;:-AOF=R69]1;=TM7^6)7"4;^`33X'3(_^@[@O%^<&XH/4N2P8W%XB[
ME['@>_B9+:G&WF7,9U@I*J(I;T$*2C<_
M)A]\C8.Y-+=N$QT$7V:(%%0-=5C7X:S'(8J8E_Z+BP].=IZII(2^,JAV1D<^
M=2(K]M0I4'-AF4A7>MHF^_#KE*]/E;=7#Y$&^?:`+$E<1+;]I+3,5Z\?C;=0
MDKA%Q5[.@>/N8'X8S@:V"\JB5T`3V%KX?H+-@Y,MK6P[9OBL\(%R
M06=66D)V%D/)?3CFM45S]B%V'049C@.VT_*FH_#("J?P?V*/+XS\5_AXP'O-
M#C;6_&O@%".U8H"'T?!Z@U^3W&$[,4-K=6/
MK*['Q!D.7;K+373$#>;C_?TGA0>L4#*8WT6^%,W_WUE)BL1(N,DW`6M-ZE55
M'%8_M]6Y^FIB+'!)D7B1$Y[-NZ:>P8KWMCEEZO"K#1%W6]P6BH8\+1<-66&_
M%42S5&LV/71^*)B:RBT/H+0]@-H2^V^L<,Q;<".`)@GL+=7*YASIW>K3@W15
M:J8`_LEP3%"D+G2N%1<.#VU!^0;U_P,%?]^QT>W!'4#DWAPSI/*34\'$_1"I
MT2\T["\ECF]F;LIIYLF+Y;C,4\8H!YZ+DA#C&D[D5+F*4VK$RIM,V,,S74#2
M>Z7?KR;X@LF'(.)[LFK-'G[678)VME"%>'>260T:M=\QTZFF("@@"$,_AAUR
MLR0(7Z8Q"`NO]:OY[.?$-D&6;B@G0?+.LN9`9R'[]0Z[\(4&"?TY28-T:)4S
MO&,C5*=(G0]PX[/D2+P;D/V6Y@3Q*\I"X9T,I!B&,!NZ!PF30Y#\V*`257)T
M-M?^GMLW:K_0H+6C4C0.G)()&CME4A=C,F*!"T!K8`44ZY6Q%$P^1!$%`E:
MU2"1H'5$D$C0$E`E2.Y)AKJ#9CU1M@FR=$,Y"9)WEC5[/@;IWG,-$J!:XM1)
MDR`?($]H(B*/Z40AU>A7:\DM6-I1]2_8)4C>":A$E91L2ZN[*>3_<8^AQ-:=
M]T+#B&?_9"4!66`YCR<3V[7"T!DY+!.(6&GL^7+D!YM=2Q1$GM>(*GH%FS3BZAP^M[WLK"/(*Q,CB!'$
M""<_PM]^CL/+9\N:_H)Q71;6O75"V_6Q'&#X'?:/#ZYO__GK__DOW'[^ECZ,
M"<->Y`>S_.'L64SEQ8WG@8[^_M.GP)]@,/52ZE]*'"I2C_]NN.<&NL`
MOT5#[[0I>SI_S(L>S35%#R,KXMVVIW$P]4,:\D[=5DB'#!/?(U,:3"D+`C@I
M';%C-&S`ZSI%LT_P]M+3\2Q$XYVP-M28CNV/YH/75ZPYM.^QE&[X8S803[_&
M'M9ADF*]HC=T4Z*WFDUM"OS\J"X=G51#Z,KITJI9NZNP*K?T:JE;NN:CZR:_
M!6[E-P*V(';#)-:7*CP>]EPC\J>E%MKVP=A3
MW?MS"+83;;N*1X*ZFVFJR&J%VS5M!;8W>M9Y2&E=E&@QHO08P8]CWP4NASP_
MZZL?T0.&E_C_DLWU@Q4Z-@%,0@S>``J3B>^1<(R!%"?$?T]CO+O^-"-#Y\5A
M&8L>C1B]V5OP![S4_DI1-.GPT@(]93U3XL7,A?1'_&,A\>,HC"P/OW!%;AV7
M?99:@0<_E`WNV6X\I.SC0WS:>:&$CD;4CMA'D:H\[#3%S6(S?[F?6YA+<-X6Y??5>)7#+DHS>DPR/`N6K2^W+T
ML/&O'Q4]5MENM7H);?-U[<`"OMMS#2+\E4;,MJE)[9,WPR\,:>FRT[G2YT(V
MY"IY-?O0+!UNZE`_CO='XB*0U$4HVC9S_H$(.\D]S1ST9+E"Q[8S((6Q1`JQ
M+K<\55I<>YE+O<,B;#NRU75HBT4J2"46\G8JR
M+.SG'2:9QL7%(A>+O*-0I47>UAE=I<.!TSGF:.K[U]-IX/]P,-O1G1'5Q$OC
M+/5:ES$'(;/^>8%J3+"VO-E_APR/&ZZ!V#$F<<(P9D8-R2CP)^PUT(AV[+).%?CF<)W>ZS$\1DF\/V+Q_@G&
M^T-",82^*J\<(Z$]\D1M*P[Y06)R?OCJQ^X0_@!/1E7&I9'O(SY\KGR(L'T+_Y_O#5<=T.'#G/J\[_C-W
M,QT,.OQT[$>^'DDZ(D3V@4Q!==AN`BR-F3::2/(T#>VP!\Z>!
M8X.(PF;,2[!CJ9\7O!.2/NE1O&T04OB,90-U`Q`KQT/Z>"`Q**6O3C2>7Q[\
MR=!A[5;84?2(7+N1-7$"BPG@XX>[1(=HQONYQW%8/MP52:=#K`E>>H"!00C?
M]"4=HY')%8@5$CZ7)MTC5D(3>`&H!8+KP`KY,:5V\E&0>%@N,=E`9S=AO@-+%M\$!]CQ]J1G+PUI
M:7PC76S?QRP*4KA3X@.;`V`_Z+)G)!7#(Y6."C=,VL;XP`1;->BI'LKK^MN*
M@D+6"$F50_9!_>/Y&NT#VGZUH\>RO!!;2$>Q2S[#OE_W=/#@!>NN;3N>H!$%
MVOUZX@,]_ZK7^JORB%]IU!*#N]LWH:-)&=U[KD$"?*?VV`.S[WG6(U%@#2DV
M[EFS3O$G_6=9(K,@,6/.Y;*2W%/D_>/W)_#[-RT/72R/
MC9`BB^51;U-)<9C:51]:0@;J\*>88J5L7EE#(Q=PBZRV>\IK:V,.R^B
MKDMM5HKM/O"G\/:L1QYH2*W`'K.SPUOZ0EU_RBJZ7=S=/_"IJ>;[VS4I,OB3
M*I90!;TIW)1:D&Y6*\-<3C==;JE&#?[TK?RP3^PW.R\6HV)WN+,FTFY!;7G?
M?6M75DE8BWPS7UF^;2%ONFO!SCY/,+]3Z9E]K9H)+ZB6+[:>+B]M)8)J&ZFF
M&DL==L6QN,B"$5DPQ]RIL:."WKWG&B1`(0&F3-.*G)CU^Y"B[!2<.L4VH^=,-UE?.O)L4`G4R6\2.1Q5]C>1W51!<:I&,Z;_*4-RJTU=1`Y72Z(M
M'A,TRVE6Z0I#J^55C['TW`Z#EI:?
MW*;4W'<_LECQQCSU$-'"PHL8\,6F;6],@Q=S!#_OC\
MQ=D5N5Y1'I+73*5AQ(J^#LDHCF(L2E?`DJ08LE,I7B%RN92=`]@KVCS*`9U8
MR)H@K9XYP[R2OP%_Z^!=%*_F+
MV<.Q6?1RX2\#^(LI8<1N_@\*#,:(+"N\'`AB@-8RM481#2J4N#QJ6=YFT+RR
M[)H"L8NU9&]\CZEE)D#W`-FSO1>3S6HQ6K;-2[&BO-D99BCMCF=YMF/Q5K_??Y8^IOY
M'@2.W,(*>L6BC[8?3/V`4>==+R\&>^?!%V.&`E^8^.'"=],'Y[_Z.O9==T;\
M5P^F%,9/H3-TK&"61(M*1RS,XQ[V2>L92;,\(\L#2EA,B3!TUHV$#/F7'_PY
M-Q(O;YL/]L'QIX&/I7=A0#Y*;XYP>27**`O)>@S:65OWF@50;_
M,^#QI:+-V!=YL9)OHEON//+%FB7;%'+AT_7C!U8R'%/S'W]G?P'T,/#Y0KV8
MLG+@C,Y`,2"U#8N1E5E.$R:`$9-D/PF25P)J^\\>+Z(<4%:IF2]MW`#H%#V.D(-[+T32L`9C[SIZ_(]S'L;/$4]04!T7UQAI37.W^.@7$>5HOV
MR-A_S5Z'QY.Q_^*B-J13QX[X'HYB,N+[(7QLXH3PR+./33X!JY`&+PY*%;QD
M9S-S/)"RI.8S?,2*4(Y1J,-TTV(Z#?#BTH]O\ZK.K,XUR$LT2ZH[ATEQ9_:C
MRRM7TQ_V&*>;;=I+Z"0T&%)8`$R:<1#X86(-N5:`KXRP+GH8T6GX"[EPWA%G
MR%8\[_EL)TS+2V.GL\.'%Y^>T@!0F7#2/H$P\4P8Q+7XL??X*KR;HD4S:A36
M(J_GC8^^O,.JU[Z-;"Q]**WH7GEXU#X7\-F,V:D$))H2EO\%4-$*WQ49$<+G
MPI&#JF/%4%>@%<$JYL@0PS]955J&?5Z-F4_*)MQ27CB<(*Q:[9A-DT
MH"IM;OOA5[G5E+`\KU2^PD!+S,74:H*_`GK6D-?N3XT[5M+?"H8H&U/D201Z
MCV]C3W%$/#\"V8,)(H%0XQ#>^'A>]UJ,QZA;I^B:`+9L1>%*8D,_PX)F2M8!R9U,
M77]&:;J9&^\37D@Q07>0&'"N6;_L1D`VJ8WD'R54'
MP^&K?\6>N)2!F1Q=58-W81>+_&#V"WD$XKNP+Z=Z]@NU4!FRHV<@=O9D]FXO
M-5"2->"D3S#63OCK0Q*';/TZZ'!GHN!:800O](#'`4`^;!D7G^\^?7M'LFA"
M9#ENX9L3&HW]M&%%]G$K2CJSO'([R_;A:RBDV+H#EH?K_,7,/=;6XXI\3334
MXE]0B-G>DH5&0NJZB#>;/!,.6S[SY>OO+?=(XYAYEXIH;F#C+
M;9RO4VV'8:BU^T4H4H?Z1>P%D1O07:!5KS<^BJ9AL
M6N9[@EVR6#Z5.*K.6"$OU==JD!598RY![XS>>DMIQ:LJ)LE),([G"-WEYSFU
M5=")]9,OGK:6W"EL<#GP@\'4E"#,EJAS&-YLJ_".;B%R3S?[%6J,YT???_MY
MG:FV&&=_M,=T&+OTV^B1/N.F\)`&'.X\YDWC2Q]FR1_KA=M/U>)3M>TMOLW%
M==)9JV]7">T'ZMEC6`CDL_6$9T#H'&ZQJ3>!PHT%:W@&'EV6JUTXRVL2!6TU
M%8IG:^01D*&31H=>,_OD\(TRAY!M*?L:.'?Y.NDB=/VY)K>Q*@DJ1U6IZ@!$
M[-;$.DRHY&CX='UEL#J7JR2>U`PWS%\_Y]EO#RGF+HU[SHY<5:'+#0^>*KWE
MGJ9I+?9R^N0'%!XCCY;;A!(_%4@?#,3-HCI0OYE"C@(Z&L4I(,&"AB!#6JH#
MV^!6=^?9_H22B\]^&+YCN:SD6Y:G(IBP#M*7VE&<-XTN3`7-@S65'LZ-(AOH
MI;+&&Z1*$&F>((:.KL^[EC:$IK(\C@?2>I*^U%K^U"@.CK1YD^--GWWN^Q$8V0Y[I0C[B[>:A@]>>STHE-\6N
M1H+.`MH$"5_^:"#!JH-#@@5MZ_D&M^1;.@VH[?";$YA`-->>33"M$M17Q0%(
M/<$6=2MW@I2E4V)!P78@L:E5A&1)7PR[B!2];N8R[MICM?74[P.E>^\YQ7NO
M:=TBE;OK*[=**K9X@FBI"1=V"1$CIX)!@047(U)?,
MHD;S0L)0Y&8C=)$4_Q'YH#E)^A(&E`5%JM)+8ST7!+W$_G$@`504$Y,(109W
M4Y#6D_K:N:48R."O+/5[/O5)[P+U3=%#?`[28=&<68*)T1N`HR\RN#L(@6&O
MGI?FZ36N&C1A
M:8D=K%.0+$L5D@"*=;-WK(F]6%K[D^4$_\3>.CQZEG03&G[S'J@=!P%\[MH;
M?O6](/WG!RMTPN^(SXYM+;.^21M:ZAY98>Z),QRZ=*?T:\`-YN/]_2>%?099
M1!B/BLV>0O)[R!O$3F/XQTW2;I+U&>M,CN%J8JQH+L.E<$T6ZU9-:8[NU8:(
MNRUN"^GA3^O3PVV*O:@61=.*2BI+-SUTOA5\IB_4)7+;`RAM#Z"VQ/X;;+.'
M'@KKMX>]WUXLM]I%B"/-J#L]2%>E9BK5G`S'!$4Z:Y&?'45;H'R#^O^!AE'@
MV-AU$7<`X7$=,Z1*2ZVN!!/;(U*C7VC87UK5,N[ZQ7)'OMC;:WL-SLY#N:):4+AG0RD&(8P&[H'"9-#
MD/S8H!)5VS=ISB$)C!U<;,KX$J+0;);6_\0>%0E:(D%+0#M#&N_\
M*#@F*')XJD29`/D"^6QTWI`R:*:%ZTDQ4
MM3/.@=):ZC*QZ7R]#)"!%K]@'23!Y#1$UM58-
ME!,FXH7,L@[:LH8+0]8C^EHW/_/C(G^*OIP?)*_-_2%Q%)CS<`H;T#%"BJG5
MBH8*(=B&R#5+/`DBSZO$_E(CVCUKQ&/WCAN([K0;J]I'?*I;,:FY2W'G$)@1
MX2@1CCI^2(2C*D"JWDSCJ*,DDM'313A*0/O62WK%-2>8O(:(6L5&@>=-Q(N!
MB%!U@Q.G#"FF+B)4[1.YWATW0>1YC:BB5[!)(Y8U55R;AK68LY5W8+SS7J@7
M^<'L)@X"[+98OSWBJ:9OJ6;MEGFJW-*KI=ODFH^NF_P6N)6GQ6=F_HBFC5O1ND:4IO<)#0UR?'.3S5O3^'8#O1MKO.+ZB[F::*K%;(
M]BUSM*OZSJM][H]6X,'N$][3X'%L!?36<>.(#C_,;OS)Q/=N7"L4-ZCF$#,,
M[@QC*@69@KMH,TJ1$,E'7JT0?Y@B$0G`(\#7?ZW2QB.==[^VF[[^U3UK66;"
M^`&)QI1\'P>4DB_`L#4%&CN%.2P'!ZPN\M$;TN$1X%PU86@YTM'XUX^*'JOV
MF5I%O;?YNG9@`=_MN081_DHCXOI5//[S-!DN#&DI4?1M'W/X@R(>:+G`-ZUG.F?;A,2/HS"R/'Q5N,AR3S,'/5FNT#KA#$AA+)%"
MK,LM(^"+:V^(KICSLM,B;-L+[SJTQ2(5I!*+>.=)8HT:F]FS2Z$!8<#M:/Q)
M5Y(FS.#=J2C+PG[>89))A%0LP/\^9D;_U/=8TE'L$EP6=>.>![_&?&W;\21V+=P*KR<^
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M5;KN`W\*;\]ZY(&&U`KL,;&\(;FE+]3UI[AFR,7=_0.?FFJ^OUUS^(<_J6()
M5=";PDVI!>EFM>(\Y733Y99N"N-/W\H/`,5^L_-B,2K6##]K(NT6U);;ZF;2
M]/G2ZEQ0^3ROKBH]LZ]5,\(%S=+%TM/EI:U`T&P#S51CJ6M*1Y7$41YJU]!^
MZZ]YBAR6SN6P=*_Z?D<%O7O/-4B`0OI*F:85&2WK]R%%V2FTPR&AI<$&+C)9ZD"J+L,A&X9+,%D-^(F^G*4CD[=2$](JM
M(\Z9;K*^= H!*HDYTD,C"J[&\B-ZF"XE2-9DS_4X;D5@MCBPRLED1;9&!5
M$&W):*8._BE#F$W3WOT6D6?6#B3RS"J)MK)X3;ASAT/!J&-_[D
MR?'82<4#M?UGS_D+/C4$S\09.5;VL6O[/[$3T.&U-_P,/SLNZQ$+?XLG\".O
M;5:L"'<=?AL5JL"1&-!D?_C]\?8G,J2V,['<$&N]_2KK9E^7I'QVS:/6YN07
MROCNO6IHL"5F5;=-F(=4JRQYNOMXV.O#-99%U#JK2&6)O"
MDL8#[EW+B^")C_`L#P/4IH8IMR4C*Y%MDT)).ZP=58JFM;9RYA"<6R6??>_9
M14W,_O;QQY1Z0R>*L09\M6*9__Y`/7L,6^-G"W9""[N#933_PHK=K9VUH6?K
M8C4J.V"L%3#6&L%8-M5V42XC\HT56>XLC-*(W)T71D',HO054-X[A7=#=[!_
M^GYP_*0IL.,]/P+F=-))PM;$$VRW_8NL'TQQ>5'02&RG[B(].X=D.24]YFO@
M%9*/H/91L7=4M=9$59',;7'E>]E7&LG[V:@T23=R&RX??0NDFM^+-*FOF;LA
MU?QN(QNRJC1/J1V1TH%4S5.JIC[NJU*_!5FJB8QI&"W(4`W-"BNLA256"Y.^
M-FB#)O44^<#06A"7VMAHZCIL4O\%/+&1$[$&MGM1T#JGT?+PVR'6O)*^7/1W
MZZ+6O*J^-!6I+:+MB%E?4MJB64T]":\VPL8&5?>E)FFM258-M7G9C*`W:*FW
M0YE:BO/2T/7VJ%,/)44Q-VA-IN4_^0%UGKU'R]U77$@?#*1LDRD.OQ5>+5C<
MLBSOCE?SFKQOMD.MW;#2-%5OAUH[!FR:E:@#X=)TU*59P3D$(DT:W9+1UI*J
MAY"I:\9:A+*#5OSQ@;Y0+Z;8^'PO^EI6#'7.E%S`H@:2+83N)=/0FD6RA?")
MO@]"[H:CKLMR^W2LJ5<54]^#(-;$C:_AEN5O-U.Y)8$[-%(-[@VRIFE[D+&Z
MV!F&LLWJY"&<3Y83_--R8WKKA+;KAW%`ZY_O2_TYYWWE"+NB8FQ$13)4C9U<074E)M2,(;J1D
MTX@R0QIT;`0[.-@]J&V=(0U8IHU<5_[0".ZDO?:R)G=67=NOV]^]@%HNI@/^PW>Q+?5OEN,M
M18VW4%Z7!0Q6?GPG%#9JKTM5;1D%)DI?8KSJ^BGVAI7"Y+)L[H$P_[99'9YM
MD1NTC1NC&,99HMDCM>.@JB-2.+1ND6CINJN!8"%#JAJ"UR^6XV+.[2<_0*\J
M'RU;];4-AWX_/_"H,$Y#>&UB@*UENY+!AT(-+66"VJ
M=C#R[K#&5;V6^&9>Q,I7DEK>=(CEPVNO>E.;"]54'*Y9+"OH`/WP6-;1"+IF
M'ASO'?2#KA\>_;K:0AFH!\=]5]W1S!SNO!>PX_U@AO<>PS&_M(4I<]]&>/H2
MO-#:!KNJ*H,BAA6&:@Z[S9$(??XNX"[8_>$'?]YY]_S(I1':&;JBEF*W>JCF
ML-M(.TU;P=D:V#U8KU^LB`8.?+P1TLFPJ1JEV*T0V07WD_J!X
M39L.KU_`[WZF7V/4%-]&CV,KH.$W<.HCRT,?X8,5.G;%LZ8"SOP[1;3OOGY"
MQ,V!+"LYXENAT?@<2DZDJLS!:'\.MXX;PZ]+W]@[)U8ATL(\6N7&IGDD(:G)
MQ/<>(]_^\RX,8]P'?Y_ZWLWFY2BJ9T=%(\%2.ID/Y0+)!>*<0C=57RYIA5>WZJT6F^?695
MK4F=5;2NE8W167\QQK>;L),/HZ.S2M*OX+7H?DL6X>5A4[N])RV%SK=D(Y@0M6%3C/W
MIQ5^"W;(<%',Y&)_U8$:0JS"$9NI5[5@FD1L>_]35N2#8%K?N905I;)UV#AM
MZWI6JMZOJB-:H_*1X;Z#QZ<,M(-3^Z@PK^VIJ>;A*7U$>._F81E:5<.I-5KO
M@/O!Z%W+2)4UZ6`(;V^!+M;I/0"VUCKBSP
M+-^0CF(7'PZ_P'N3>%+UINA*P_/7>_U?:0[QTM=K#*[-#[[>ZFUZ\'4S7V<,
M_GH_J(&']0/_?!L'RPYI/4[(4AD6\\/L@,V6K&D9F_J\V@:QSF_\J\K*SH=L"LV-K.T&FF74+-?W7#-TA93'@.,6:Z[5#!.T8BNLD=)V?W4TI/13&8?'@@=47
M#^E7P/O[*W5?Z!>8Q+C^^8)6_?AM,Q:[S>E?U`J^O_KU[Q94#N*N'KR!&8QA
MAZ@]!Z5R$&G=\+O/XI,?!_5EJGJ^SNK1&Y@#/%MW#J94.=5C]>"[3>'!=UVT
M.$81#7:=CJQ43X.HALG2Q:?A_\+>@Y;1)S]8>6Y;*:>ZA!O&_+VF56/MA-3Z
M!.D2I.8U9V6DTHO:W[Q;)YSZX&#`0]]&G/I-4.MR/OUJ[7@[([HB=N?9
M`;5">DOY_]]Y;#O^-F65)D`X&R/?W$V<*H,VA^JVQ%3T.2VU';HLH%(LM9;>
M;KNG`7@[D?5,6VE5DGQ^Z:[!E=9/HCP;D-IU`KO6Z5P]`6,_$RCC`-@N:2`@
ML4F;F9.L'HXIQSZG,CY]\V@ZIV1*VU0V73FE_IY$KXQ-B=.)5D'&+BR:N333
MY,%&)CP8U)CP3:%`99`L``00E#@``!#D!``#M7=MRVS@2?=^J
M_0>LI[8J>=#-BG/Q)#LE6W*B*D726,[LO*5@$K*QH0@-0-G6?/TV2-UX`0G:
M$@%-31YB648W^_1I-)H`"'[\Y6GFH0?"!67^IY-6O7F"B.\PE_IWGTZ^36J=
MR66_?X)$@'T7>\PGGTY\=O++?_[Y#P3_/OZK5D-7E'CN.>HRI];WI^QG-,0S
MPOXYM??^WX`WSD!?2#P;735<_2F_AZC6DU#YX0MN$,V
M"EMG[]KO6JCYH=T\;;;.4*OY:ZO^-(4K=G$`?Y=?_ONTVVK)_TYO6F_/6^WS
MT_>:UPIPL!";:S6?WC?A*LUF.Q+_Z%'_Q[G\[Q8+@L"-OCA_$O33R7T0S,\;
MC!FD;"%_JZV;U>17M=9I
MK0WL"/=D[?S0@YQYY)I,D?SY[;J_N:IP*/$#.J4.]=V%"#@EHNZP64,V;`!9
MBQG\O>.[/6@5+"5S?!8:#F!"S?><3#^=",=W:S(09)3(R_^D(QLLYQ#I@L[F
M'CBGL0>++YGO$E\0%SX(YE$7(M2]P)YT_^2>D$`4V:VOP83U8\Q!_IX$U,'>
MRZ%DJJL(E^SY1$:(&$U'1T^^*@-X+MELSLD]M($[[#_!7QC6Z
M6$;3_=O3P]R';B!D!AT3#KEUQOS)/0R)1>852^[?VL^,N8_4\R#01C!BO:7TW+0/-(E`:9>F422D*C"NE9Y\UI&,YVF
M5\MK,HEFB+G\XJ&P5'F!RLISN293Y;280E'83TJJ.>BHI.EYM425XY*FL=H*
M#-BNW7W+:ZI^G-7DHZ0:8SBTN7FNOCQD#O:*N]4A0
M>YS(AZ^EOF;TKX5J:"VU^Q'[+HI4H)B.2F"4F)N/@3D%!)NI1OA\.1IV>\-)
MKRL_34:#?K=S`[]<=`:=X64/3;[T>C>3]0+*&I/'G!@.3Z[@,!Z/DA6,<)EF
MBL5MN%:S$+4[C.<-&3T-X@5B_4T83[5F:[5D\]/JZ^]1_%PNN)R=7U_`P[?$
M"R_[?=4NT:QASF`Y=ROK"OC1@^KO`7MR".L$EQ#[2\A?X3BG!J(IG@2X$V4=
M[B#&7<(_G6Q&3,R=6&REU\]6+1I"SBE(-34*,;*6GW(VR_/WRK?L.5!V>0$K
M3M`CH7?W06B]01X[#Y"QY`W/%>,3,'U"G`6'4IYH!&.QJ!Y_IT;YT_:`?=Q%
MDV#BFC@$X@X@#$E03%NNE!YC;;.,:>"VCJQU);T$6]7DQ%OID?'&*!E9N*QS
M_IB3.:9N[VDNBXEU^:8YZ&H)ZU%U9I2J$EZPCL$NF1*PT+W!3Y'!.JDN5TB/
ML;=&&=-`;1U3UT06\0[4Z=F5D9JN8DD]SMX9Y4P7OW7$Q5<%53
M7)Z*Y.RHL15,Z8&VCJOUU)R:E6T+.\IJA?^30*SS]$[1.&2^4U2#*9K;42\K
M.,B%:!TA646B#C-%RVEHPVS3&2SGEHCW/E&QO
MNGQ44Z"89LH&;%UH@;E\0=PR$98C8KJ:+,-2/FSKB+I%;"&A"Q-FG,^.X6G%*Y*TN-175:^?RE]HMU
M'682,.?'/?,`@9"3E\%2W6^RVAHT_883+!9\&9I5L"\GJZWIGJ]V?2(!J(%F
MA%/-MGBZ(%/&20Q#F1#+%#>=';2I*^4.ZY+#3A*$RKE,JBB6--W[=+&I!^-R
MM!D@73(1C*:AF1/(<3E3D\F&IM-Y,1$*
M;/:5B*OTY-^M-NSEW*EG-#6Y%A^>4":?DNFX,^I3$42/PZR,R\E(18*FN[F2
MDN0BOIX'K.OW$^)Y6W0Y23C1SG2OU^4E&Y]U-%P30<`''7D00'4@@C0E/*H5OU):K)8QWD+3C,QZ&R4-K7]:2D(;,9_&.
M4A!760+&NWHA.058K>-F'3R%XWZJH?&17J.C9&*S+]EN!XXK0!DM9RT@=K9S
M1]%$==3N!C\1T7N":A]\3'W,EWWP4[B)%"3!A5X8=L4I\(`7-9U%*_"H:FQ7
MG9]J6]EBP$49/=:^?+A"NTH:%W"3G3O!J10PNODO7.XNC:5(SHY>K024V@^H
MXP7K(G"]Z;PT>X6"=F0<7?HT_6`=?T,2Z-R=)YJ9[EJ95J?JJ<./&%8.E?K.
M*1.F-7M7;,L<#A];S3Q[SFKFY>CK^+KW!=KU?^NA_A!^[Z%7@]%D\MK@\F8&
M;HB#T10HSENJRA'Z.RF5['<:%"0WEF?V5-N&B+`0S@#WS><$>_1/XGYAGGR+
MSV=,?8EDY&\/#.IP*N!/7?C5OQL33IE;')>'NZ+IW%P^1@[M_:/:FY/_JHQ8
M;G_[K-S>F7Q!5X/1?XT>?.?^;Q'-F(H;=DV@_G!H>)[3-E?<,(E^S-D#!>]>
M++\)67EN;NH[\K57!3O9]WL5HW<@T#469WOVYG)_=-_QHYWS+H-
MT9$V/;0<(B12-S#Z;K1NB/KKWH56POQQWKJ&)P!?X'"(F$F+"[JZJKWII8$*
M*,YWE77,`G"YR9UT2?2S[R<>/,^=X"P2-?W<:05\:SOP"*A//BA=AONTK.EG
M7(V0KW+A$;"?/LN@9-]/29M^>M94]U>XT;H8V+F/Q1X93;<;2'*HSQ4R?D3B
MX1G7<)I]&PEZL[G'EH1,"'^@\HF;K"(%ZM%5(7J]FN^0T_F])\(=*@!I^-31
M:!Y[9B4='P>XE%Y4O3_FJ#H80?;%HKIBVAZI_9RJ"F:YWA9E\W48?)-"'BY
M(C-\BS`GZM=QJ;&64F)I=\\A-_DNA?(NLV]42H%0OB&B!.TY.BQ-?"]@O=!A
M1T!Z\@T3);A.BYI>VMX_Q2KW[)-9Q8&6U\0ELWE4X6[GUW"B/#I_Q(]-25I>EEZ_QU5X1QKGRR82$?Q
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M1U<-M"!9YX%,%0!Z*;MJA#MI.`]-JBJ(9_"JK5:G\AP0IZG:0".A5XVL*+/G
MX4M5"9KYO6J,.YFK2P*X@57@294-R:RWDC9G=RO;\%3EH#`LBAG6PZCHFZGBHR3(
MZOKLSOB:2UNJTDB.S173HQZ<!BR&73J:S4R20;JI(
MR(3TS+Q1PA:@'6,QLIW+_OJ5#!B,+5LFQE*ZZ(.="2?(]M??GV=
MV^`941<3YZIBU!H5@!R36-B97E6^#ZOMX4VO5P&N!QT+VL1!5Q6'5'[]SS__
M`=B_+_^J5L$M1K9U"3K$K/:<"?D%W,,YN@1?D8,H]`C]!?P.;9]]\]N?/<=C
MWYD>?D;LVV6OE^"D]AF":E5"YY#XU$2A0N/TO'5N@,9%J]%L&*?`:/QFU%XG
MK,<.]-C?^9?_;G8,@_]H/AEGET;KLOE9LB\/>KX;]M5X_=Q@O30:K:7X%QL[
M?UWR'V/H(L#,Z+B7KRZ^JLP\;W%9K[^\O-1>6C5"IW4F9M3_O.L/S1F:PRIV
MN#E-5%E+<2U)
MT03P_[\_]L)>71,CQ\,3;&+'\EV/8N363#*O\X9UYE=_SO[>=JPN:^6]<2?3
M>0"DJU+`YX;,%Q3-6!L6KGML49BC/G'?3RY#KPJFT)W=VN2E
M`&Z[FHIG,_3G334CR+>_2RU1TE
M#OMH+JV8!5U"M'B\;?-O'[M89M%(:'J`48"FG/'6>L36*#8J3?:E9!3*H:)X
M_+<0TV!G-9C<8H<%@,\5C&[5=5V)?
M(RNO*NH6&WT/'X6W0M439%;,!"X44!+AY##G5E1ZM)/CD4O)02.?'%ZA0)E1
M4`ZJK'SY$5$.?SXM!XTC'>1!;.<))#L29:`S\L,SE$8Z2:OFUZ22S3VD_(OG
MS*W*.U26'LLE/95/BRH6F?,DIYJ#KDJ2EA=+E+DN28*55J``N_3TS:^I_'56
MTA\YU2CC(>V;??6E,8/47)-+:KP-2%`56!#G@-,`Y8RJHZ8]1U<)SGCKD
MR9551]O6"[5@QZNSIO55FWJB@L/C#CNK6F0.<4[0<>D2$`<]5>=H/D8T)]RH
MZ.&Q0MO.AS`0.#PNAWCMO-#6,J6.232!ONWM/2C7XE',[&OL!'OG/OLU@AN]
M>LBQD+5&SA466,=C7W-]C>4_`U3!6FK[(W0LL%0!(CK*8)&C,A?ATF0$PD(#
M^WPSN.]T[X?=#O\T'/1[G?83^^6ZW6_?WW3!\%NW^S34A5)RA2["K[4//_`I
MHOEGA7PSJG<1KB=R7(=/[+^[[CWC.;@%@X?N8_NIQQIHPC*KC!>A?+H/Y9O!
MW<-C]QMKU_N]"WKW[/Z>#I>[HNP/MN+=7OX#=SV!W^4Y.B5K%KVL3U*6*_PT@?(!+@;C0"&*L$BU%D&/YER8834YUU2S1I@2L!&
M"]A54P:/I+)B!/?%+NY6#42$2AE-.8J*V^B-QB[Z$S:4ELJV5^E@\=[55P8Q
MV8ICA)2Q2^JT!KBBY:$R/D5"72"BK`Q&2?7)"/KF+OJS&H@(E8%2HDP9`=W:
M!7U>`VL=;/%@6GX&;'T&9J`(N$M-93"1+EY&^)SL\OE<`VM-P60(=(&-,K#6
MIL_BD;J(&*?O6D38'G#UJ:1-@;@$&F%UEAZ-P:>E<$F@\]=`(V1BZ[QT<"Z9
M9[X::81C;-F7B]4E$Q0752-D8GN!:.@N&;1T>76;0S.V(Y"(Y"43RUEWC="+
M[0TD`WO)%%,*M1$ZL>B[U2F$BSHO.M21[;GK;X(R1+5AK$[Z
M_[3Z>A1>+S.;HA[[&-*TX1C90=^C5>.DMG4-H`<35`+VJMTNY,VX:M,U^%7R
M53+#ONO9=1M-U5Y/#;;]BF;&6+%:H#Q-K55D^B[I"X*\T
MS@GN4^NH)<;.JO(E=$RT6:&.B-??LKR0:F"2!ESDA&;CPWEA9"1@+LH1ZYK3
M>V/D8M8-[.MJ[Y4XV?*'6!^
M%&-].>1"\Q=L_VM,%I28;(ZR2[XA@\4V).FC7B@P2HJB.E@\`[)P45"[--\0
MNN#3$ZTO?(5N64D(!$9)\5*U6R0@"\._:K=LRI3!`0=V89GM&9',Z$1GYZ2B
M%OGG1/&.%MK(?43/R/'1/?)2=E/1AB-#U8(A?4&8!%CDA8+W2+>$(CQU`@B"
MA6&[B<;&3(:JY]79`R43[&V?^(@/XTT;C8TNP"I<>8L=O,N<+ILRAF#H;AIH
M;,,DH,(ULE@#]HDSM?$SLH+^NZ\+Y%C8\ZDP%H@%-#=P%G#AHJG6[6'^@X_UOM?6M4EXC<+
M1`H4L7I__@(%"+LXEBJ.I8H?ME1Q!_]+Z`V;B62.:$9](JFMWD4),3O=]KK\
M@7"#201O5CX\141-A2+%VD06N:8EBB+=HW/IXOTN++5V\?1"0K"I:=MX0U7I
MVNRQ3S)A%YZR%9AWX*!U]ZG6C;53E=?+9=QDU(7G]40I);:SW$PTQY*U=:;<
MZ/0#V%Z.A?!2I6!?W/N\R\%D#4&P#>)MDYMJN@L2`RXI];3;N7#-3$*J:#.3
M:;04XQYL%W,X^VJY&WF_#PZS#3D>#ROY>-B^F=SC\;#C\3#MHMKQ>-CQ>)@N
MQ\-T/'@ACUQXD5;P_G7[S`&_<8;7'A_8PLC@P"D2U5,SI$;GNM:29,&+S%]P
MZ(D\$F$O3^30H+=7\A*1B$^JBGPY'TL8J>O%[GB5O8'R>-?1L93WHY?RPHEU
M_19^_(81Y&_`VL@[9IPBINA=HOSDJ
M<*J`EC",:Q+'MV`W]W%A4VVU^E`N;!ZRFGTX%[;V<6%+[8U(AW+A-BUA(%7K
MPN5Y\?:870A",^5>F&B[T86NF0`QW*(S,@7=+`;=&3_!R_[C.=1G:`=I;N\&
M4OJ&G6DPI,1ND1+7WEOR+/2\)'E$/(-C>LA*9B+V7Y:D]JZ3(B!(
M;7Z9?$LH3Q@.D>G3X![&&Y_2K3UX0C3,$M7>;W(,]*PY+X-[N.!NLIU9RU>"
MB/Z.2D4NK/(H=5`?PS&V@]&4O;-(:*R]4T281>XX*[SJPY^^R8#RH@>V5@\Z
M3RGQ)#979>8,ZQ%)Y")CGW^4`H[@67BQQWSFK.#P9^1I4`B)S:%C#>=8PRGJ
M=JPGUHL[F'30.'@3"=MO>F^;+8S$/5HR"O2NXN2T@V[73!+PLW+Z.50HO-LK
MAXMR.UCSVDV9/M:Y9E/2.-"Y8+.+."M+G-Q>T8'(_#.12)(I.C8++ACN?,^'
M]JWO6.F'(F/M5-7%]K:XF(6F93!Q(F;U7`K^WB-WKUQ41(&^A_?VX%'2M!%#
M"B_P!!-)0E)?A^0A4'1J5^")[PY%T.9CX!NQ+>Q,OS*F@L=><0%A>[VMG@Y;
M(ANK*N&1\CKG2&XC]GJ/W3=BE/M^`OD7.T=8Q-[K(?5.#,VHI3\?J+7?>S\2
MG@RDQ2M`TMS9VO\=(,;[OEMD5]_LB[W5EU_;9\EH$-W8R<6RXE
M>N?=]K"';KFW%`H;`OQA%9FG:O,J4G2,>@^723L]S6+:9>14>5[G[%SIHT/G
M/-T3A1::0_I79H9NMZ6BW-R^,Y-DDM$S=@=(.1\Y!VVU5';&O3@/[;(I/*/(TV4G8<_7W6%A`1+F>*7[6P>J#-([*7SZ:=X47VNQ;$0LH.
MH!^=3!=[D-[,<0OW*NK/\DB>9(@X_1$<]\C!>(C%"N#\!]CZ"+V
MS?\!4$L#!!0````(`)9Q;$>?/=\N>#```%NX`@`5`!P`&UL550)``.LY$16K.1$5G5X"P`!!"4.```$.0$``-U];7/CN)7N
M]UNU_P&W]^ZFI\J>MKLSR71/9E/RVXQOW+9CN3.;FMI*T21D(4V1"DG)5G[]
M`N`[\4I9`HZ3JDS+TCG@O4$X"=.(
M)(\_OODR/9Q,3R\OWZ"\")(HB-,$__@F2=_\\;_^[?\@^K\__-_#0W1!'B9S-(?T'6PP)_03SC!65"DV0_H+T&\HM_\^;\ODX)^%Q9DC>FWY5,_
MH=]^^WV`#@\MRIRFJRS$38''W_W^P^^/T=''#T?OCXZ_0\='?S[^]GE&GW@6
M%/1W]N5_O#\[/F;_>7]__+M/QQ\^O?_>\EE%4*SRYEE'S]\?T:<<'7THU?\0
MD^3K)_:?AR#'B%9CDG]ZSLF/;^9%L?ST[MW3T].W3Q^^3;/'=U3M^-U_?[Z:
MAG.\"`Y)PJHSQ&]J+5:*3._XX\>/[_BOM:@@^?R0Q?4S/KRKX30ETU^)1KZ#
M)">?<@[O*@V#@K/!^!BDE&!_'=9BA^RKP^/WAQ]HZ^31F[KR>0UF:8SO\`QQ
M,S\5FR5E6$X6RYB!XM_-,SR3@XFS[!W3?Y?@1]K@$7O01_:@X]^Q!_U[]?55
M\(#C-XA)?KF[5-KUL5=6I?3.-=A;G)$T.D^V0SW4]@2?OCM9\0(#NOK.3;A/
MBR#>"GQ7TSGL:[Q=C;=Z[FN:]@!XNYKN:.X%=B%"'EV]\GJ-V9=7]%,/(GXN
MEIV&OW)AY\S3KVYZ'"6N2X^]8S\FMFYY>G_WM
MA/;\\R)=4M@I[[DWY_]8D>4")\5GO'C`32G3PR_3-?]5ZJ%5$C2;ZM=3]GS^\:Q^X#9TJH[A!LR!_
MX%:M\L/'(%B^8S1[A^,BK[_AQ#L\.JY&`_]>??TW-M["#-?)*B<)SO,I?F1_
MYI-GD@\JQ5+'!?%&P6>\LU+P3KLQ*`765:*HED6_,ND7\TSAMDX#VNMN\N(.
MYYC6TOR2#FJS%7^PVFU9*#ES6]8&-&[+J.&=/Z-@#@E4ZZ%:$74T=^:V5+T@
M29=9&E+^TCGPE*+`"PV/=-+N^CTCY+;#4XK"H(P1G^!LN@JHT@#6M9VFV9)U
MOWB21#?%'&=2/AFE779G!LC=CDPAZIU/=O@$WU-+HR")$)<'QZ8D3V,2L7G0
M>5*0@F"Y@[)1<,LI$_`^K532@)AE@"B2JU4`QJJ+@&0\U'F9+%=%?H77.#[6
MTDJKX9)7%M"[Q-*(@V&6&>.06EP$'0,CT\FF^?@SP1D;RVTX4LVDSE;9"\6L
M#)*R3:L)CW@V<(<<9!KE>LD!:I1V-/G;GY=[/]K+O8?BY=Z/\W+O7X&7>V_A
MY=[#)=.'T63Z`(5,'\:1Z<,K(-,'"S)]@$&FR3H@%$*,9VF6!S&>XG"5FP,/Q1T=LR6
M!HI-:Y=FD&:M[9)^(TWJLM!2%0P9Q^$="NCY%+>B>,%;PA<01/`8,]]UD0X460?=7S1A1SR1@5R"Y7AC)@6*(`-N3'
M/0[G21JGCYL#5#0J,$AR01)2X"NRQM%E4E#4A([.)GF.B_QDP[O&TSC(=:.?
M424XG=>--ZTWS[-7!T/(\9B%L!4OX9`7@=HR4%D(>MB@W7Q.EH:U()V&T\4@,_3>:I!:'`P3S1B%]:!*`V5=%1C&04=/50\Q5,`H:#1B$.DV3@AW^H!..
M._(X-]!)*>UXQ5H'>;!<+1,%0R0]OB&-KM/D,$P72US`XQ'?DS'LZK5&7&..16N:>&M..L@.OL*<9T_Y36O:PFR"23\,,0`3.@(FAA(FMV_7_PM^R$FA:'&IA#-7((?6^('^
MS]Z;6(UIV+JUT+Z;]O+V+DBB,W7+#@2<-:P46-.NO5]A-*L,TK!5J0S?L72V
M[V8]2T-^[I1ML&)'?#8L1U"VX*LUDX>Y5@AQ^&WC^GZ780)&R;\EGU@E/MM9W1`O_I;B>(./Q*&
M/"E8%S:P6BWF@E(FD(Q!*AGOA#$`$W8ZE91H97E^,'^T.,5L(2>^3"+\_">\
M41HGR+DEA@)FGQD#(4#4D"-3<*,21EP:47$?[*C]&-O5*S&K_[,K+LA`U13H
M_@:BY26`E)T%D_'9RDVB-Y;I4&/+0,YUNTMA#@G0$P+%!!DR)25*83J$B'CZ
M21_LF%`@$0-S$0>/$KL&O[MB@Q16S8+>CR!:7X9(.-53RR`FY*.M3U<9"UM?
MD#P,XK_B(%,[`[6H*P:8P-9D4,F!X(4!G!ADYN*HE$=,P:MS*`;?#20/L_K!2(0R"1#8(A6!'7D],`\0T#[\R553K
MHE+YC_Y(]9)EF!4OMQ;-KJZ=?"G''U'']-,'0$92+GECA1BGS(]$4!,D>%21#ZX**IE/;J7=+%(DVF1AE^G
M\X!6R^FG
M>A)@2"2%)02AI]/S^RDD*E130RM&"++NB:&`*_)C(`B,)G)TJGATJ?,)!FU.
M@WP^22+V#TLILPYB=M!T4IP&6;:A@WR>T4]AO*6NTP/#8\SI'1^V401#NS%H
MQR#[A5AT'(.TQ?(A(6.)(;J:@1LYI+&MH:T66@20<,^2R!#GG7
MJG'FP6!;DQSR(LVFO9R2E;=6^7VSGI>\GR8SI(D_54I@&&>+5(BB)VM*.CZ>
MSX$E2IN$8;JB+\L=#C%]<:AMU[@P<$ZKXI1N%N![3-/(PR&9&:3\X$I0*:*L
MT3Q`"2Y@$(V]`PF[>(Y:H["\+^*22#)P7>)T?P=#%`DHF>-A(F#49GF&**KH/GDOKC)V@5L,E#2V@=^FG$0=#.S-&(7A?::`B>(;B
MZFR&7R_NU/+@W$X%B#%#JY4X1T;;JY2#@H4IGD!:-RM28NKYIM)"4@J8P7G
M]!I@6&<%4QS1#]+E`:+:3VD:/9%896_[LTOZ#$%UB5+_!H82`T##QJ]_AM'<
MGL\YZ8*KI!MN9?FDG$#XF7.J9%L0IEG9N!7E!CV(ABK^XVA?TXH_H9[>UTP?1K(P$+=SA>3DXNKR[O+\^G:')]
MAJ8_3^[.?[ZY.CN_F_X&G?_YR^7]7\%1U6Z7E$[!$QTM]DNII2%2;MS.J8XB
MD.U3]:+A;;!AZWYV"[A#81]+MW+`LD7;OB08$FGA"1LUZR7:92D-@SQU7LQ)
MM`YHPQEBUDII'[<&*2#+;@P:B((AD!Z?\J:@H!*'0:$KDK`;2$_I)(`85L[D
MHFX[,C78?ART[=^793QECG]9>JK_'
M)&[5O#BI*YS7>&]+]HY_?61E`'%=:O,LO9A8P&MP:$K4XWU;3(L"[^#,[Z0W
MEV;P96"=F-9[[=!K[2K1P,6:%[!DLSH11B>FZ=2^`W?%5=L@`3(
M.^F'M$>)!3&WUPS+0?;O%^[+@&&+`IC83?%L3GF9S>G_?7OT'>V@,K1F*C^@
M8%7,TXS\DT[]?G]P='3$_H]RGO+I!W1\\-W1]PX"$B"H_,@2VAOD'>0G^$9"8EJU&BCZ#95@ZTA_60-)BTPS+2&
M*B9L*!41KC1A,$\<'9_@69KA^PP'^2K;Z'IS2UV_LQ>-.?J)C$01#`O'H)5.
MF&&0KP=7-Z&1";J]-U0%M']SZ%`*#&&4T(0=B#RZUIG=H#F.(T2'?T55Q$%[
M/.SXX\'W1^^KF0T,2HEOAO4KY-M3V;DE6/$Y)3YYF"Z7A%9@\,:T<=<V57'W(6F*5HG!)U<.G)Q3AHK#)I+XVQ4[%*ZT4
M5Z;8R,,EF/FZE#[+NDMDD*C6FT^7IMG,O&M);[&+/E1E\*(4`T,C-3;QR@%Y
MR`(2=\KUB^9R!,.^$*6TV\R26LC]))-243!9`'MS@J6P#>_
MPVNR#E=A`DA=@?]_1$P-!"CDL3\-IR/59Y').64^]C9T+/
M(^E5P-#,#J?@M$HM])_!8OD#"GJ:,%@WQ7'N(ZU2.)VKU8#!-Z+1M.W?/0R6K(1*LD;4*GGS!/Q5&1\`(TVYE-MG;E?1"
M&A&JE#:M&%#B"`"%'7!L9L8JH:9/F@"AS76:I'TSZCM-]%,U"SVW26BG
MGC$H@>GA;)'*TQR3,N#\MG)8WP"9SK5WOY4F728%IA6GNP-++N[Z/BP=Z.'=
M6#)9,+0R`-1%2S
M7S^=$Z3<>A\IQ+[3Z8FXX7*H>8\,@"">OV;EX
MI2KE[
MEJ_M_)D.W=(L(DF0;2X+O.#75E!-6G4Q=Z2&\=`>G^A^(\A>JT[<3+*7Q\%Z
MM_9OJ'2:^\`+K?OX(GBFWR08S)IDE3&J,;KJB$Y*C*J%>(.2VP3/-@;T\SSK
M-,",)*U@*C93,9I5G0)Z6_'MFT^H*A(&\^J[8,91SZCEXXZ?$>0SJ(!AGQW.
MHT+XU+#0,9I1%@&KQ?][0K`
MHHD,FI!A'!>`DLW4J4OJLXDG04Y"A74*69?DT,+MDD0J"*;/TJ$3KSJ@OS6)
M8M!;QIUOT+),8,1/Q[`28++IC,2K0GF"3RGMDU$#R#I.5:)@6=7')]QP6/ZZ
M=V:I$C\'^3PB:Q+A),HC',;T41%%7CXZEYQJMU=SE][9WH@VH[-9QSNC1@(5
M-K933=2HHEK7&;72)&*#M(@EGTYC$K'8=G-JA]TP(V:04ZR:[Z`\E[G&7VQV
M-^_XUH4!H>_++9#D(R^+1-TRVP-A.;J9H5ZQJ)IG7AD&?'#&T^^]MYX>%^SA
MM(13=5Y*P[X<*TW'9]!M31D<13>I@6&8/5;YC'.T`"GF,JF33E"_Q>?77`M<"@KZCC!TMUG*9O_1R>9+SI;FFAWWD[`@
MZ]+)&_:I;U&0XV6*+0T=S+U&E@*&Q%M#5Q];#AH5(./H2?3W5;EQ.K]/[S"C
M!8EQ;V)ZG^Z&[_MYE-O[4_976?T;5W;_'#!OU1Z-$V]U:1Z%BA1E]
MO$[Y7R'K<%8L\$62SD$Z<.]K9S(1Q/AFUAY\4"UT:S6<)A@P0^\E%U"+0]LY
M;H8JW8[(%@FH/!OOD%8#&L_.2+Y,83BM#PG?^TL\Q9A]8MHX%N^_TGX'D6MQQJFXW(MH;
MT]^-:-8#TXF/`"NLRG=4>5[ZH*/C:05I#YM'W:XRK7'VD.98YS1L`8OM5>IU
M=OM!22Q0[RQB*Z`+9HS.4ZB$G<9ZM(![41ZI))CW7PM/FJ7V\(%)\P6E6AP&
MBJF]"4F-;\\DQNAIUI?!S[;I'B'A*N$FBR#O$^N;APO3S57
MG354.M:^^3;8;-7U-GHP^MV!&7:=;J4$+4IE"UC9W2Y+,:C4.UW12=@"9Y-H
M'=`FM^]P146_Y%,9HF??4`L^_12(A2E+)8:"2@XJ`>F+DJUHM]!.H<:\B8*J
M=P^H,,;H!`=Z\(FHQ"QQA4RPWST#BMI+P@-L[-!N[]"M,=LJ>P[P:`PR!'TAVP,/U%\.
MC6ZKP_9%UI7@U8N:3=,Z5+4Z>-]JA"ZL=U%4\R#'-HSFGA@PH^EXAPZ^B\TM
MM;"8)-$Y_9;?+6=;>YH"O/+9:)B6SDIM\&PV(1?'#'P'5AD=CDBQRJ#,O033
M+I."(B?TK=*&A"WTO#)398:6D$,E\#Q4`-;YTOKFC%H15%38?G[XX@DFU)G_
MRV;\KR*(I<:M#&(MJR+0PP:]K2):WU3C@E<4TKH@29"$.PAI:0L"0&P+0RT(
MKBG%^_SMQ="'7&\T`(:TLC3$..+WQERQ$,G-[#3#D?*N`(V\TT&!"79O,*`2
M!L,T$T+A\#&583U^R(68"^7J,"AUAY?58.9F9D,IC;S;&],-L/NWI2N$P5#*
MA-!`J:Q1WU/4\[9!5UY7]4C_8#ERJ:?-9,=.;96=G.ZNSWA@A!3])'($8"519ZZ8C!H902F_9"@O8^`K;U
MDRT0PB!/MX^_3@ML.("A%O?F%,GF^EZC2QV@AC>FG6+/3`="DCP`HIV#JJ+/EG&*WN(1UE+C"MBT)+B:Z(6SZ(X/ID
M:'\'Q`0!E$B#4F1/"WT\'G:?5J&&(&[OOM3=H&JCY6RIS]Z$9JW/K.*=(N-P
M"I-IILAN>VA4.[>:PO`F4_*8D!D)V4;>,IT-NQPNC4E(J,WXN3BA#_^JZH0M
ME9V.@489U!L"66EZI^16<,6Q^6(19!N^X->6@X*F(+2L2MJ7Q\-/'=19FM"/
M8?EBJ%@W0L^=UQMA1NOW+)2\TVPL4C&0^(1:7=17AN'[&A,,39.WLF/2.!G_XD;GC.[QDMZ$DCZ:8EU+9VK\29QS)/!=;\RW?!@I^PVRC;&H'[\S483##]'P94G
MR5F4BZ%4'95I`#M?@_.>%P')^'KOB/&D0<::9U:CIY>"F?C5C!7_W!=DT5&X/3&@HYO<9."K!W!UU/`HPW
MDL(:\J$4`N=R^&FH>1I'.,M+B&PU;L1TU%[?Z:1TK%F]J:FM,A@&CD4LD#/(
MV*;6'+UEN8^_87M\V'6@"W8-.KL'$097?TK3Z(G$\22)ABEMK$=E(\MP>C'Z
M-N;U+DH?4P`8[FZ#>LC?N@P>6VE+064QD(=\-7)[CZO5\,%72Z^J$0?'17O/
MV6->'3D9\`\&T]BY^S0F$0\Y\@T0&Q/5]"I.SRE9@.\=<]#(@V&;!4C%<<\8
MUZD1V@)@L$RS%:*TT(YYXXMQ>^9S.R/[)S_'E0%M2KPE?J?[7U3Y8JI$A_1E
M"O$DYJJJ+#$J47>Y8?1@VXPP`TG.-H%>.;
MV7!)NV/;R:;ZT1C[V;8TIY&@EYG_MK=0I@>&B#4K-]
MAV4?:8M`=1D%E!7(MO]IUE-/RTOIK9ROO;J?\86=4?(!A5X7VMQ_)&[P2^.M
M/?5"V"W.IFSAZXS$JX(EN3KEJV&G<9";C_MM6YH?VFYELIS%HXH"XW5?AE^Y
ME`IS#;4U]H(DM&NX(FLLK+N-=,SP:3Y:H&C:FRCO>EJC\_S
M$?C=6[7)0L0[?YCWE\F5A4+"IE(&U&U=NZR#L5`B5VM&\#51OS
M_O4ZP>'\C>\ZO)\'B>+U\X3AM7:*UM6[K\[1"`#**^W3^.'K?@/YPMI=5I"S
M6>AKGWZZF7?^"T\XM3/->W:K+^KOU(/ULG63$=4[N.[P&B=M8GSSUB]1T_,V
M/)4IAJUW0S5PA#5CE5W!,0UB*&N(.D,HU#)!,CM=MT5%#/2A4%!JEBT1>\JO
M@HXRQ#)25KFP8RH%A)I!3L+AVF9ME:HB]#I.*6@#OT<[G0(;:%;43HJ56"0
MNLE%?J^Y$',HY#;9@0Q@/Z-!5P(,B:2PA'WFM1#ZE8L!.;C=P+JB[\$E_:@:
MV,D$O;!#`"IE2",%CR5#:!JF,%'$9;5T<5'MM:>LSDODDV>B;P&9@N-K]FSV
M@%K!51P:82D%J1B45YG-(JO))NV.5`8/I9R^Q'*(/?[T1<#Q10IOR(]*8%^[
MR^CX!)/'A&.1K4_U?W>VN"B#U2P*=G_T[I-5B(1C+Z4(I``-'9[.2*&)P'0%
M7+[;(K#N:]W^ZKWQE9#DMX%5N:28L>B&CNYWD^M8M6^4!ZNI8SF6[FOL_.IN
M7Z@`J=T'VOSDO5'E>(1]GOO<\WN5)H\QVYG,GW+^O,1)1`J6/E:&52?MK&W-
MD)NV5HO":'LCOB$7F,(AURBW@J.NCJ?1]AE>9C@D0;ES>1EC?KME$DT6[(#S
M/X64&6/TX(V]1Z$>-E]7F>\PZVIY:K[/P=_3['25%[3;R)0S)%$*7M-H,(J;
M=4NI'(K18/.+N9U4_K5F[7##4>L-`I=4HPDVV/0X)J@Y(FW6U?`MY00(%O
M_-1JG[6\#DC,5E4NTHP1ILT[41TEDE:\20E@6UA#%IJGUF0WWO,W`N6-,HS(
M5LD@R?4K6F)*Y5W&O8RPQ9==(@R.:0:@THV4,'C4W0*JSZ(NE73)'0W4+FLD
M8MX[:C,V(>#22G[:W]"/Y8&CCI`-`$A416M5XSR%K,M!G19N=P0G%?3.`AMT
MDK%9)QUG;:0XTSR6Z,U%/USL/M\(K,S/=U
M/E4-K.ECI2L:-FKNEH+LC6C7B,PZWMDS$J@Z.>*>R/,ER7`0,_+^G,81]9T_
M!221+`&;A)T1Q0BXH8=2$@8I3/"&5&CE4:6`F$9U(=&>Z-%)1&>1;$@G[8P@
M9L@-0]2B,"ABQ*?)&P@KV5"3!?$N>/H<%#@C0S.YSC;"TL9(]1]'*'
MH]$0Z4V.2BWOA!L-5=B8%CRA1@$8ZWY)LZ^7;/M]B/-QM--I>N&=V10I\=1J
M\)AGQ#JD'E-@J7V7I0HP\K'$@OF\3,SS*->2T5G`^!1AC1C
M82LM[Z_K:*C*Y,-LUH1H":@L`O$R;`;->WR+CL/T![C^7P9)LT2'D"
M_&V\B[GK;OKK7S!YG!!$E4W6P1*BI@9!DN^_"M
MS.MR;U0!WAW%2U`+P\NJ#!24A?22EN6XN"C;CK?$+_>5LAL."7:7*3YR3-;S-'8I77&7R.$>A+L4[OWT\,%*YUTY/AQU
M48C#IM'D+5%E^`#?/$.@PMF8\O<7-=&+=N'P^5Z1AE\O\WS%UE2_+-/D_!EG
M(K>(K,E/M9+53=7K?Y@AC
M>O=I6NAYI_`68(5U?BZ`F.Z^CK'4&.@3/E.@B]5"ND%!(N5NFX<28KN_0Q#Q
MWOQZ7+J61I6H@Q8/GMF#SE99[\RORH*AM!<&R"%+F=`7A<<(*3X],TH5Z%U1
M_E.FSAQB5H/1!?6-L.M^2AUH`WM+O/O8I[IWIDW"<+58Q>P$GBQ]@7U-*`L"
MPD:#H9;\5)3BW3>^&+IXUUXC#2%G@\8NQ3*]7@->],`2KV0%<$_CG/H.C$D2
M\?LNAJBJ]=UCW7K^^#*`EJU85'B):#RNM0A$M;ZQT`
MZ#K(V!!M#>3.!IV/['@ZGF@HQ]?XN;A_PO$:?TZ38K[%J,RJ4"B]I'T%V/:8
MYA*]OQD[-4-8]LL+LN#]Z&S%LE:AH%,4PF59B'+U=Z_Q]?@K#K+[IW0G%=J4
M!?=E&)B[_3M0%?1*J=]'OS7C?_]J&4\?/SY,;"@-..N[)K^0]ZRHU\S\#OZM
MN?_]:^7^!:W]G55E61ALYG<-?AGQ64FOF/<=^%O3_N.KI3V5W5U-\L*`T[YC
M\`MI3V5?,^U;^-O2_OW1:Z3]71K';&/CK,#93E\!><%P7P==16S_:LA*?:6O
MB<:4[5X9%E'"`2L.QHO3;NZ]2#.+A1*-O-.<,B;8O2PR*F$PI#0AE-\;*R.8
MXV6,$2GZHS1T5M?T62M6F\K="P(N>5II=![SVWF^]5*M>TIW`ZLAK`$#;*$3
MG(3S(EU>!0]IQCSTYOP?*[)D>#YCM@==:!^C!JS6L84+L6U(6AWUI_WW=).S
M6\Q4C:(4!=8:)IP0FV&'5ZG7:W-B`^[A(<":?G\6`B3-:9#/([(FU*XHCW`8
M!]06EG6;[];F9P<$#ECHP&I2>\`@6X@.0*D'8GDOJ,[\,LF+C-NKA5-(X7\ZMKIB@U]2Q-N6T:'[
MF8+DO5]A5:\,&L#ZW1P\GO\7)S$:?A5J'X;)5@M,@(QQ$;:^GY;6(V@1@BP
MTLVC2N"CR%*#^9L;2?)?;I3H7;`TVD@C-,K8`6.VU)7J`#;GK
MJ\A!-=.K7:C@1W_.R&R&6931T-_KA&&UAP52B(WQE#91+U43""+`*EZ%#V!U
M[^*Z.%"5;X()L0UVDLD+5BN8<`)O!ON4>F"KO85/W-DB\@)8_5R7VIQQ>$`-6S&MNPMAM)5(OZKG/]
MC902,8CU+D&GKOG+ZG+**]/EE'NL_LNDP+0VBHH%LJH?B`"J=A4R\4K?4J[F
MNB^JESEE6:-+*=[^#*B.9:@$2E1K7-S,*$99FVC$`;6+#4K)
M/6:M3G]PTL0V2,>1&G%`S6>#4I@_49W:;;)[YJDB
M:[&.JO<6.B/Y,LU)N0-)'2C6*H!L)1U.0SMU5%EST?DO[>**#;JE2@5J4N6P
MKBV,5_SFP!L2\SC$3T'>RK,O[@E;1VN^\W5]Z6(9IQN,ISA;DQ#7M['BB#D8
MZEUX_TT=2>7W[ZIM!FR(T1ZMY^$926:!O3T$$*_V9YN0;[!Z$JH>A?BS#A_8
MPU#W:0>\RZX>B.HGEL.S\\X%E_RIZ,9\J>5^!U@9IA:NV%*,MHQX@EHR"*QF'<27TME;_!E&W5)>`VB+`-"+KR)(BS10+,5H%T,TF
MPVG97AU5,.UTF^%E0")M0$FO`[JU%%`M&ZS2]AR(4KN.*EG`./=8*8%N-A76
ML8ZQT@?3<,WQKVC--H!8NL:A%NBF4X*U;+M:']4%@&D\RJILA2/#%@,;/=`-
MJ(%K__JQ$I#_/0NB=3SXW2SJJ&>U=IJ@&U(+V+(IR[6"=A&L+,779K4F9W9^
MG[)DF$E(8A8I:R/?]RE+LDBGU"S+8G2R^9*SI.]M)80%62M?W5V6#X@9>S%+
MV'[7/H0%&9O'\%!D?Y6`_LR>ANK'H8<->LN>2`GW39=KS5,]\8U"?P&;[+4!
M<64+T))K7%])^]8GD^_3*GMNG7,7JR_\-ND`:DMKJ,,6K!79FUJIHE;W`'%M
M*&VF3B=OU7QJ=<@M:8':IE&;8@YG:7:8LS6(MB0H#5S'QWF(?9)$39#=JGV5
MVI";UPS:IG7K4@[*U8F#9CH@K^CKFI4FM=IO&
M)-R4_]6VV]@R`+7EUM!%/_F$VI)0OR@Z?.'%H%^K?_VW^S2-!M9A34%#(,^6[2=/H)$G:3_9%`-%&A4R<4W`1OAO;:WJ'
MYE[-=O0L7?Y2"0.J>S-&5:X4IL.3<.#.),)3LVANI%8N/)AT`#62-=1A6Y6*
MAUQ3YL!4"P_=KZ[H)_IU_17]#]L?2[_Y7U!+`P04````"`"6<6Q'G^)4:=,?
M``"2]@$`%0`<`'-C;F0M,C`Q-3`Y,S!?<')E+GAM;%54"0`#K.1$5JSD1%9U
M>`L``00E#@``!#D!``#M7=USXS:2?[^J^Q]XLW55V0=_R)[)?&QR6QK+GJC6
M8WDM3[+[E())2.8.16A!TK;VKS^`%"6*)(`&10J0XCQD;!D-H?O7`!K=C<9/
M?WV9!*4>BA@(3XYS?/7__OO_W+8?S_]S]&1<^7CP/OD#(A[-`PGY"_.#9KA3\X7'&**8D+_XOR*
M@H1]\O=_#,.8?>;&_A-FGV;?^LEY>_P!.4='@#[')*$N7G78>_?^_'W/.?UX
M?GIVVGOG]$[_WCM^F;!O'*"8_9U_^+]G@UZ/_^_LOO?CI][YI[,/P.^*49Q$
MJ^\Z??EPRK[E]/0\(_\I\,/OG_C_'E"$'2;&,/KT$OD_OWF,X_FGDY/GY^?C
MY_-C0JZFCZWW\^/$D_6O>M-+RY8$&
M^7>.+P?[_=#5??&KD^#F-_XKM^Z"513'T<';MD=L(;GC"P
MDAG[>S_T+EFK>,&1H[-TX(R9M.='BB<_OXG>DA1%?D-##880]]D-$`M]C&NI]1@$7__@1XSA2C1O>@XG1WR+*Z!]Q
M[+LHV)Z5VNYVQ!>?^9AK2#2:C.9\$6.:T0P>>5<&^+D@LSG%CZP-6X.';*6?
MX6L2;<^
MAD_LKX0"IEA-T_;'T94.*%7]GDQR7.UW(@4GJ]F.)".4\TN^ET5P)*
M7DRQRWT).%AP!P;&#IZ^^CWM?I\%XJ'9C3$^P-@T[4_&V9SBB+&0+LS7[(,-
M$OP2X]##7MX1YZI%3S[[F/=WFOW7-M?_`.$-NG'<4H`<)Z+NADY4(T;+%B?SU/%_Y#[ZP4J=)I3,=$6Y%!M1,%*4+AO"
MSB&X2*T=MKUZ^.5O>"'#H-(4"$+//A0$7)N`(>?CGG5;+_W-%D"AG]DD]#H>
M3.5'+@K^B1&5*KZX-1"$=S:!H.+=W,;[&PZ"OX7D.1QC%)$0
M>\,H2C"5;G`H-00B\=$^
M)&HY-C@Y,I]73-SOJ>,K&B5QFBC+E$0Z1:1TX%.=??A`!&+RW)&9(9D=?L4^
M$RQDDN90<*PZMV2+%PL<>XNR6'4
M6\^NYNQEGG\U(^5VICR]6G+=G&("3MI?Z[9%8VE90D&I-#?F`)9+N`X&`:MV
MH,$3O'GR`?OG\M^)_X0"-M2H'U\@2A?,=DF#X6)T@.3&/,<@($@3EFP"\0[S
MG5@QVH]9^0'_!$MBM"QVR`8^PFE*WN..=6LBBJ
M28WYK1O@!I:$)!"\"_'4CEN5$+-D`Q
M,INMC'FT&R!1QY\=DK^E>(Y\[_)ES@]0>3;.!F]B0$#$QES=#7#2D(8=\`WP
M!+-A>??H)1LE9(63$AES@C>`"\"]'3`!YU.SF=.^%[S)7J.8(VSL&5;7&=?"
M$:;#BTF,@K2EX<61S#&-%[N)F3;Q0!S?@/4#Q
M[?<#G0NDB@F,V9;>4\\BT+MNQ`20/'IS(VAC8^"=SL`NO9#
MS`M_L;W85[O\ZEN#P[W60"/CV@Y<;DB\NJD\KI
MPHF!M%`P.O-?P,'0X,JFR:,S:[:9+ITY,!KL/H!YLN,CK,A:&-BHA;.[#H>U[J[T3!+?*]87B!YCZ;W(5!
M2^Q[`"T4K\Y<&MIXP25B"8*NF\R2@-_C24-\@MKM-S@>3>[1B_2XIM<1.(_:
M'FR;RWFMM@(S`\RO>TFV/0@M%,[.G"?:<,(E8@>"508_XPFA
M^)YB%"5TH5AO@>10'#OSK;1@N$CD8@>4&T-36#%U;:$@=>9ST09)S+$=B%09
MTIE)<$0Z\[&T,&T.Y62G.@@U3S^`XVR=UP7,805]?KGI3;NKY\WN;_N
M_+#1\Y]?[[,?F"O'PLRB/73BL$DRHBG+7FH7W&*Z\4B-U*\C)C9]'WX;3X]*
M)-9AF%7XZ2?Q(Z'^?];KM!2[*I'I6_';8"82@:58I;7]='#*"4Q??]\>HTW6
M+<5'7CY,Q%J3XF'VG$AV73*LI?-[-E;@`3YO;/IZ^W8'^$V6]Z%(E>+QU0UK
M_RW,VA_?LW^^7MXP2W]TY8QN+^_Z]T/6P*"=GSFA5V-76\%"`I/6/`IP=(>?
M<)A@?O%+?KVPOK5A"UZ!0]EHES!LQWIW02)V&$G'-B:!U&PH-31MANLA(>#3
M#A"^4/Z\#B436:AFHY%I>UI/^#7\[;LG^6
MS"H-_!O"$AV>0N+XJF-!4!I*8K6^F9
MC&!9V+&<\F*#49P]7,P'.PQCS.2K**Q83V&\6A5<]M6*BS(AV`%5FJ]995&R
M;(H(C)>K:@J40@1VX)1KC]*(K#0T7LBJ^02J95E_7_N8[6LAGG*'M_F=;?G<
M,&">Z"$P3:]"'9/[CEQ^:2U/#?V,(M\5(RAH;KQDF!Z24J;M
M6"G+0QSX01++$BV%!,9KAFV'38GQKNH;H>C1\Y]\#X=>Y&$W8-_LL2&X:2IA
M),@C3RN00"B-5P0#8@!F2`B&U0E[@HO6*W8VLO?>-NQA]O;V[_(6U&_YZ
MZ0QOV.^7S@_7H_&XV;4=<;$@;4XE<8!E)9TMNCQ4VZ.3)U[;0$_3-C&;DEYF
M)J]LH`Y-@8B-Y09V!*:&Q.R`6%3%XEM(,0KX+99?2,"S[[\@/^0:.@K7+]'U
MJ1^Q/PW8K^$T>TA:726DNV\TG>NH`WZ-\[A#%.S0-8E\&BTCYM,AFR,.D,5A
MW[_>6&>9W7H5D&>!.?=C(W.N/_[%N;H>_6;)(^(K'K4N6]=0F;77^(!N*>%G
M#._SXEO$O9>KU)R^&[/31[HFJ3-7&O1ESZ5L(9I5XZZAQ.Q8LKOU#G86PVTN
M];VQS?O>OY(LZ2:Z)W?8):'KIX_.K@=\3UJ;K=U\FVF#K34]Z1(,.]2M8'BB
M`(\FZYPOR;(@)3)MNW6*&8'+H:FQ9UNNSYK)@1_-E[5*1A/58UT*,M,W:(QH
MB42`^Z\G`\P&[OHI@NSG`*=0AEY_QNM\_P<)*J2O8N80:M-7?':H-3KBM&,K
M,9[_T=TS];N$73=W9$\?>\RCO-Q[,.,L*A8(47O35Y=VJ!MRD=FQ"%S.Y@%9
M8#S&],GG9?CJALS4>JG/=TLW*,^#O'S!U/4C9D>EA4A&\XTZ'C7A]?:_RO3E
MJ1TJ4V=`[;\EPX3-*^+@`<[^+8AW6?,=5'T%W(?IFURM'9?U!6?'HE4==_Z\
M))N#V'_B#]?H0%U';?P66`-P5.B*I72(BP`_W8?LVZ1/`RG(C%\QZT`+:N1R
MB/#?4CQ'O@>XOJ:B-'Z?K0,EJ)?.(>I!Z>7A)OO"BM3XK;@.-X62?/;_Q%IE
MM?S(L8XN5&EMN,36MC*()'2(VE!]"%9S;:A0VW!9K8/E02"E0]2)-`%L?9!2
MQ$R@]#;]K(\;+@1F&;
M24.ONL(YSM(YF!`)G9X0MEQ[;E@MEW_YWX%'].(C_$;#^.
MTBJ^8H35E,;O/6X!#M'DU;SE(KBH=H<]/)MG.2CKA*7"M8,GY`?\Y'Y%*$]K
MJ@&<]Z/?C?$;E]NCWXQQJZ=W>;AK1C1FNJP3*.R[S@9M8=*K9;?_)Y<*TTR.
MS.*)%[TNYT0R2G_5<)N,S:.#S`E:0SIVEK2J(ON0,]<"Z?RFSEP"GM"ZH[
MG3E6VSMP`F1FB45*B8NQEY9"O.9G*,8Z4UM9PK"$!(I@9T[++>`@4"9M@N\.
MSY=[V6@"A$]"`H5OU]Y"??B4H?/>6N?.IO(
MR6:$^TQ=*5TPS?P5!8DVM!5R**8=O@+>$J8"R31V-IF%"0B^DR^P!2WPM$#56%SCQ4#51!1RYV
MK/)U(QZ&$T)GF:`;@5G;`13/SEQ66N"H<95(R0YH"Z_BW")?XOZH-(1"U5T^
MF::\!2]6;#)N"RK9`T0J2(JMP$6`;,6CRK)E]=?'R6R&Z&(T&?O3D#?BF0?9
M!2U>5)8$C*QP!-LHS_G>.7(&?N0&)$HH9K_TCIUE?PZ9.-&Z1P>MNG3F>9\M
M^K13Y\(]61X>4;"N,:JHH`XA-+E)R4"Y9[!_9E_^7;)'`>E-5E:'8U?>F[2$
M8]F\N\'/A4%3$K(?7;Q9&6YCLGTH3[:S8X=UXJQ[<4K='/3\$@U4+%;9=$F'
M"B+=KYD"Y\O*29*F/F7E\.HGQ:]-G!#7KO=91\N
MWQVMG8>]T_(\?,LLP:PSI]";@T+/*?5GT+C*!GB'Y[Q@8C@%'/F%%"9MQ-*@
MUCA`#$0(L>GJZPJP55].L3.3CH!5$>1^$"R?SUY_!*BW:F/NG97GWH_'3I'([!SCHUBLAP>;6$(BHY[#RK@`DTE.9<%<
M4N!3\26JA=!R@123LQ\$[)"WW,T%5\PV9MK;\DS[<.SD/:4'O+0O9]V9
ML^S-X`L5:T;+/.KLCYK=F'R28SE2K=DI)3(\'QLA6'YF0RT4RR8H+#@G#=+U
MWFT5I'-^R'MO]2UD^^()+66+K=XY9)J02FX!F'ARJOV*.(!8LBDM01(>R<8-
MAE&_)Z./(#?&MJG$#NAT4G#WW_,+#8*U]T=Y>,KY(2-NMK3N;9Q*="\QH>XC
MBO`M]5W<#U)2R6U$46O;XT;2P=NT,.8%JPH*RR;[%8_E%$(Z@'51NR/3KXA"
M8W\-)62;D:D.^LG6N$H2&#CT9\/R=R@Q0/<1>PE_8;(\O`($GQ?+/T(\-4T[
MW+-8X79RLVPF*^*'LEE'.5Z'GHW
M)*3YKY]1Y&=XZT0=M^K=@H#*]L')%N1KA_'V%='O..8#7)<